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Currently the treatment of individuals with active Mycobacterium tuberculosis (Mtb) 
infection involves a standard six-month multi-drug regimen, impacting negatively on 
treatment adherence, which in turn fuels multi- and extensive drug resistant TB. 
However, some patients may not require the full six-month regimen due to less 
extensive disease or rapid early treatment response. The identification of these 
patients has been problematic but would allow significant cost savings and may 
impact positively on treatment adherence if treatment duration could be shortened 
and if this subgroup constituted a significant portion of patients.  
The aim of this project was to identify peripheral blood lymphocyte surface markers 
through a proprietary technology, FACSTM CAP by Becton Dickinson Technologies, 
to investigate the change in expression during the course of treatment with potential 
treatment monitoring utility.  
Peripheral blood mononuclear cells (PBMCs) were isolated from TB patients (n=33), 
healthy community controls (n=11) and other lung disease controls (OLD, n=9) at 
diagnosis of disease, week 4 (after commencement of treatment) and week 24 (end 
of treatment, EOT).  Antibodies to 252 surface markers were used to stain PBMCs, 
the cells were fixed in 2% paraformaldehyde and data acquired on a FACS Calibur 
flow cytometer. Post-acquisition compensation and analysis was performed using 
FlowJo software. The analysis was performed by gating on the lymphocytes and 
overlaying sample plots on isotype controls.   
Statistics analysis included repeated measures ANOVA, paired t-test and 
independent t-test. Comparisons were made between the expression levels of 
patient time points (diagnosis, week 4 and week 24) and participant groups (TB, 
healthy community controls and OLD controls). Sample wells that provided an 
uncertain demarcation of the positive and negative expression population were 
flagged and excluded from analysis. After the application of the Bonferroni 
correction, results revealed five overall treatment response markers (CD120b, 
CD126, CD62L, CD48 and CD29) that were significantly different (p-value <0.0002) 
when comparing expression levels at TB diagnosis and EOT (week 24) samples.  A 
comparison of expression between TB at diagnosis and healthy community controls 
showed a significant difference for four markers (CD48, CD18, CD126 and fMLPr).  




Due to the application of the stringent Bonferroni correction, only these few markers 
were found to be statistically significant therefore all markers with a p-value <0.01 
prior to Bonferroni correction, were included for analysis with Ingenuity Pathway 
Analysis (IPA) and Qlucore Omics Explorer software. 
IPA identified 23 biological pathways that were associated with two or more markers 
with significant changes during treatment. The top nine pathways are discussed and 
included the inflammatory response, cell migration, differentiation and maturation 
and crosstalk between cells of the innate and adaptive immune responses.  
In conclusion, this project resulted in the identification of three promising biologically 
significant surface markers that require further validation as candidates for 
biomarkers of TB treatment response.  Future studies will investigate the most 
promising markers, including those that showed a trend for differences after the 
Bonferroni correction, in a candidate biomarker project with a new cohort of TB 



















Die roetine behandeling van individue met aktiewe Mikobakterium tuberkulosa (Mtb) 
infeksie, behels ses maande van multi-middel terapie, ŉ tydperk wat gevolglik 
negatief impakteer  op behandelingsgetrouheid en dus bydra tot multi- en 
ekstensiewe middelweerstandige TB. Dit mag egter wees dat sommige pasiënte, as 
gevolg van minder verspreide infeksie of ŉ versnelde reaksie op vroeë behandeling, 
nie die volle ses maande-lange behandeling benodig nie. Alhoewel die identifikasie 
van sulke pasiënte problematies is, kan dit beduidende kostebesparings meebring 
en moontlik ook ŉ positiewe impak op behandelingsgetrouheid hê indien 
behandelingsduur verkort kan word en indien dié subgroep ŉ beduidende deel van 
die pasiënte uitmaak. 
Die doel van die huidige projek was om perifere bloed-limfosiet oppervlaksmerkers 
te identifiseer met behulp van ŉ patente tegnologie, FACSTM CAP van Becton 
Dickinson, om sodoende die verandering in merker uitdrukking tydens die verloop 
van behandeling te ondersoek vir moontlike gebruik as behandelings monitering 
toepassing. 
Perifere bloed mononukleêre selle (PBMSe) is geïsoleer van TB pasiënte (n=33), 
gesonde kontroles (n=11) en kontroles met ander longsiektes (OLD, n=9) tydens 
diagnose van siekte, week 4 (na begin van behandeling) en week 24 (einde van 
behandeling, EOT). Teenliggame is gebruik om 252 seloppervlaksmerkers van die 
PBMSe te merk, die selle is met 2% paraformaldehied gefikseer en die data op ŉ 
FACS Calibur vloeisitometer verkry. FlowJo sagteware is gebruik vir na-verkryging-
kompensasie en analise wat gedoen is deur die limfosiete te selekteer, gevolg deur 
oorlegging van isotipe-kontroles. 
Statistiese analises het herhaalde metings-ANOVA, die gepaarde en onafhanklike t-
toetse ingesluit. Vergelykings is getref tussen die uitdrukkingsvlakke van verskillende 
pasiënt-metings (diagnose, 4 weke en 24 weke) en deelnemende groepe (TB, 
gesonde kontroles en OLD kontroles). Proefdata wat nie tussen die positiewe en 
negatiewe uitdrukkingspopulasie kon onderskei nie, is van die analise uitgesluit. Na 
toepassing van die Bonferroni-korreksie het die resultate getoon dat vyf algehele 
behandelingsrespons-merkers (CD120b, CD126, CD62L, CD48 en CD29) 
beduidend verskil (p-waarde <0.0002) wanneer die uitdrukkingsvlakke tussen die TB 




diagnose en EOT (24 weke) tydstip vergelyk is. Vergelyking van merker uitdrukking 
tussen TB (by diagnose) en gesonde kontroles het ŉ beduidende verskil vir 4 
merkers (CD48, CD18, CD126 enfMLPr) aangetoon. Aangesien slegs hierdie 
merkers statisties beduidend was na toepassing van die streng Bonferroni-korreksie 
is alle merkers met ŉ p-waarde <0.01 voor Bonferroni-korreksie ingesluit vir analise 
met Ingenuity Pathway Analysis (IPA) en Qlucore Omics Explorer sagteware. 
IPA het 23 biologiese paaie geïdentifiseer wat geassosieer is met twee of meer 
merkers met beduidende veranderinge tydens behandeling. Die belangrikste nege 
paaie word bespreek en sluit in die inflammatoriese respons, sel-migrasie, -
differensiasie, -maturasie en kruiskommunikasie tussen selle van die ingebore en 
sellulêre immuun sisteme. 
Om op te som, hierdie projek het drie belowende biologies beduidende 
oppervlaksmerkers geïdentifiseer wat verdere ondersoek as kandidaatbiomerkers 
van TB behandelingsrespons, regverdig. Toekomstige studies sal die mees 
belowende merkers, insluitende daardie wat ŉ tendens in verskille na Bonferroni-
korreksie getoon het, navors in ŉ kandidaat-biomerkerprojek met ŉ nuwe populasie 
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Chapter 1: Introduction 
 
1.1. Epidemiology of tuberculosis 
 
Tuberculosis (TB) is an infectious disease which is caused by the bacterium 
Mycobacterium tuberculosis (Mtb) and was responsible for as many as 8.6 million 
new infections and  1.3 million deaths in 2012 (1).  Approximately 13% (1.1 million) 
of the newly infected patients are HIV-positive with an estimated 75% in the African 
region. As illustrated in figure 1.1, the incidence rate in South Africa is estimated at 







Figure 1.1:  WHO incidence rate per 100 000 population per year.   
The light blue areas denote a lower incidence rate to the darker blue areas demonstrating the 
difference in TB incidence globally (1). 
 




The Mtb organism is a slow-growing acid-fast bacillus which is transmitted primarily 
by the respiratory route (2). The disease is spread by infected people who transmit 
the bacteria by coughing or sneezing and although it can infect other parts of the 
body, the lungs are the primary site of infection.  
 
Although it is estimated that one third of the world’s population is infected with the 
bacteria, only a small number of people will develop active disease (2). The host 
immune system is capable of containing the infection even if it cannot eliminate it 
entirely, which results in the bacteria entering a dormant state and surviving under 
adverse metabolic conditions. This mechanism enables the bacterium to survive 
long-term in humans, sometimes for many years, emerging only when there is a 
disruption in the host immune system. A number of factors may increase the risk of 
developing active disease such as human immunodeficiency virus (HIV) infection, 
aging, drug or alcohol abuse, diabetes mellitus and treatment with corticosteroids 
(2). It has been documented that live bacilli may persist after successful treatment of 
active TB which could potentially result in a relapse of active disease (3).  
 
1.2. Problems facing tuberculosis  
 
Currently the treatment for TB involves a multi-drug regimen, which must be 
continued for a minimum of six months until confirmation of cure (4).  One of the 
limitations of a treatment regimen of this duration is that it may lead to poor treatment 
adherence, which has resulted in the emergence of multi- and extensive drug 
resistant strains of Mtb, requiring an even more aggressive and longer duration of 
treatment in order to reach cure.  Patients often feel better after just one or two 
months of treatment or conversely the side effects from the drugs may be too 
severe, which results in discontinuation of treatment.  Evidence has been shown that 
patients who respond early in the treatment regimen may require a shortened course 
of treatment, which may improve treatment adherence and thus the treatment 
outcome (4).   
 
The only currently accepted biomarker for treatment response is a conversion to 
negative sputum culture and smear microscopy at month two of treatment (5). 




However, these methods have their limitations.  Culture methods are still the gold 
standard for diagnosis of TB though problems associated with culture include the 
long delay before a result becomes available (up to 6 weeks before a culture is 
regarded as negative), contamination of cultures resulting in a false positive result 
and the high costs of the assay. Smear microscopy provides a simple, inexpensive 
and fast way of diagnosing TB; however, the sensitivity of the test is poor when there 
is a bacterial load of less than 10 000 organisms/mL of sputum.  The test is labour 
intensive, requiring a skilled microscopist to examine individual samples, which is 
problematic in high prevalence areas where large numbers of samples need to be 
assessed daily (6).  Thus it has become necessary to find alternative ways to 
monitor treatment response to chemotherapy in order to improve clinical 
management of patients as well as to monitor new anti-TB drugs during clinical trials. 
The human response to infection and treatment of TB is complex thus it would be 
likely that a bio signature consisting of multiple markers would have a better 
prediction outcome than a single marker.  The most useful markers would be 
biomarkers found in readily-available bodily fluids such as blood. 
 
1.3. Mtb and Immunity 
 
The immune system, crucial in our defences against Mtb, is composed of a number 
of biological processes that work together to protect the host. The immune system 
can be categorised into two branches, the innate immune system and the adaptive 
immune system (7).  
The innate immune system is our first line of defence against invading pathogens 
while the adaptive immune system is a second line of defence, which augments 
innate effector responses and also protects against infection during re-exposure of 
the same pathogen. When encountering a pathogen the immune system has to rely 
on both the innate and the adaptive immune response to ensure clearance of the 









1.3.1. Innate immune response 
 
The innate immune response is the branch of the immune system which responds 
first after exposure of the body to pathogens (7).  Once the pathogen penetrates the 
epithelial surfaces of the body, it is immediately met with phagocytic cells which are 
able to recognise bacterial surfaces and bind to them. Once this occurs, 
inflammation takes place, which involves the release of cytokines and chemokine’s 
by activated macrophages into the blood stream, which attract neutrophils, 
monocytes and adaptive immune cells to the site of infection.  
 
Features of the innate immune system include (8): 
 The recognition of pathogens through broad specificity receptors (pattern 
recognition receptors). 
 The response time of the innate immune system is immediate or very fast as it 
relies on preformed mediators. 
 The innate immune response does not improve with repeated exposure as its 
cells do not generate immunological memory. 
 
The innate immune system consists of two components: 
 Chemical factors 
 Cellular factors 
 
1.3.1.1. Chemical factors 
 
Acute inflammation is an innate response which occurs in the event that an 
infectious agent has penetrated the anatomical barriers (9).Humoral immunity, part 
of the adaptive immune response, is primed to recognise and protect against 
extracellular antigens. Chemical factors play a large role in inflammation and these 
factors include: 
 
 Complement system: Once activated, the complement system results in 
increased vascular permeability, attraction of phagocytic cells, opsonisation of 
invading microorganisms and lysis of infected cells. This is the most important 




component of the chemical defence system and a vital process in TB 
pathogenesis.  Phagocytes have an enhanced capacity for engulfing and 
opsonising Mtb in the presence of activated complement (10). 
 Interferons: These molecules have an important role in protecting the host 
against intracellular infections. In TB, Interferon gamma (IFN- γ) plays a critical 
role in macrophage activation and restriction of bacterial growth.  Studies using 
IFN-γ knockout mice have demonstrated the importance of IFN-γ by showing an 
inability to control bacterial load and dissemination when infected with Mtb thus 
resulting in decreased survival when compared with wild-type mice  (11). 
 Defensins: These are present in the lung and gastrointestinal tract and prevent 
colonisation of microorganisms. In mice β-defensin 2 (mBD-2) may play a role in 
controlling the growth of the bacilli as well as by creating a link between the 
innate and adaptive immune response by contributing towards the establishment 
of a Th1 response (12). 
 Surfactants: These are produced by pulmonary epithelial cells and, based on 
their location within the alveoli, constitute an important first responder of the 
innate immune response. Surfactants function by regulating opsonisation and 
phagocytosis of invading microorganisms. It has been reported that mice with a 
surfactant protein A (SP-A) deficiency are more susceptible to invading 
microorganisms such as Mtb (13) and SP-A enhances phagocytosis of virulent 
Mtb (14). 
 Cytokines: These are proteins which are secreted by cells and are involved in the 
signalling and interaction between cells.  The function of cytokines usually occurs 
as a cascade where one cytokine stimulates the release of another (15). 
 Lysozymes: These break down the cell wall of bacteria and disrupt the cell 
membrane. 
 Interleukin-1: IL-1 signalling is essential for the containment of intracellular 
pathogens and studies show that it plays a key role in the production and 
maintenance of granuloma’s in Mtb infection.  
Interleukin-6: IL-6 plays an important role in inflammation and the activation of the 
acute phase response (16).  IL-6 is produced by a variety of cells including T 
cells, B cells, monocytes and fibroblasts.  Previous studies have shown that IL-6 
deficient mice develop normally, however they have impaired immune and acute-




phase responses (17) .  Unsal et al. hypothesised that IL-6 might play a role in 
reactive thrombocytosis and increased acute-phase reactants seen in patients 
with pulmonary TB. They showed that patients with reactive thrombocytosis had 
increased concentrations of IL-6 and those with TB and reactive thrombocytosis 
had more extensive radiological findings and symptoms (fever, night sweats, 
weight loss) than patients with normal thrombocyte counts (16). 
 
1.3.1.2. Cellular factors 
 
Haematopoietic stem cells can be categorised into myeloid progenitor and lymphoid 
progenitor cells (18).  Myeloid progenitor cells give rise to granulocytes, 
macrophages, megakaryocytes and erythrocytes and lymphoid progenitor cells give 
rise to T lymphocytes (T cells), B lymphocytes (B cells) and natural killer cells (NK).   
Dendritic cells (DC) can arise from both myeloid or lymphoid progenitor cells and 
thus do not fall into either of these categories (18). During the innate immune 
response granulocytes, macrophages, DC’s and NK cells act as the first responders 




There are three types of granulocytes; neutrophils (CD15+), eosinophils (CCR1+) 
and basophils (CD22+).  These cells are short lived and increase in number during 
an immune response.  Neutrophils are able to internalise and entrap pathogens,in a 
phagosome and undergo a process of maturation where the phagosome fuses with a 
lysosome to form a phagolysosome. The phagolysosome is a hostile and acidic 
environment that encourages the degradation of its contents (19).  During active TB 
infection neutrophils are one of the first responders to arrive at the site of infection in 
order to eliminate the bacteria.  It is suggested that neutrophils perform their function 
not by direct clearance of the bacteria but rather by targeting the pathogen by 
degranulation or in assisting the transition from the innate immune response to the 
adaptive immune response by cytokine and chemokine production (20).  
 




1.3.1.2.2. Macrophages   
 
Monocytes (CD14+ and CD16+) circulate in the peripheral blood and differentiate 
into macrophages upon migrating into tissue.  Macrophages are one of three types 
of phagocytic cells involved in the immune response and they play an important role 
in innate immunity and chronic inflammation.  Upon inhalation of the Mtb bacillus into 
the lungs, the alveolar macrophages respond by phagocytosing the bacteria. The 
macrophages stimulate the production of chemokines and cytokines which attract 
neutrophils and monocytes to the site of infection resulting in the formation of a 
granuloma which will be discussed in more detail (21).   
 
1.3.1.2.3. Dendritic cells 
 
Dendritic cells are considered to be one of the most important antigen presenting 
cells (APCs) due to their ability to stimulate the differentiation of naïve T cells.  
Dendritic cells recognise pathogenic antigens and migrate from the blood into tissue 
where they mature to perform their phagocytic function. The cells are specialised to 
take up antigen, migrate to the regional lymph nodes and display it to circulating 
lymphocytes via the major histocompatibility complex (MHC) molecules in 
association with CD1.  Recognition of the antigen by CD4+ and CD8+ T cells plays 
an important role in the activation of the adaptive immune response. It has been 
noted that some virulent strains of Mtb are capable of inhibiting the maturation of 
DC’s and therefore their ability to present antigens to lymphocytes through a 
decreased expression of CD1 (21). 
 
1.3.1.2.4. Natural killer cells (NKs)  
 
Natural killer cells (CD56+) are part of the innate immune system as they do not 
have antigen specific receptors on their surface. They are able to recognise and 








1.3.2. Adaptive immune response 
 
When an invasion by pathogens cannot be contained by the innate immune 
response, the adaptive immune system is called into action to help eliminate the 
harmful pathogens (9). The adaptive response is initiated by dendritic cells that 
recognise, engulf and present the pathogen to lymphocytes. The activated dendritic 
cells also secrete cytokines which are imperative to the immune response.  
 
Features of the adaptive immune response include: 
 High specificity to pathogens. 
 Ability to form memory to specific pathogens which allows a faster response time 
of the immune system during re-exposure. 
 There is a lag time between exposure and response to a pathogen due to the 
need for clonal expansion of lymphocytes. 
 
The adaptive immune response consists of two classes:  
 Antibody response (humoral)   
 Cell mediated response 
 
1.3.2.1. Antibody-mediated response (humoral) 
 
This response is initiated by B cells and allows for the production and secretion of 
antibodies. These antibodies circulate in the blood stream and can bind with specific 
pathogens that have entered the body. The binding of the antibody and pathogen 
prevents pathogens such as viruses and toxins from being able to bind to the host 
cells thus interfering with the infection.  B cells and T cells do not work independently 
of each other but rather complement each other. B cells are professional antigen 
presenting cells, which through their activation, progression and interaction with 
CD4+ T helper cells can stimulate T cells to produce cytokines. Reciprocally, these 
cytokines can aid in regulating the antibody responses of B cells (22).  During Mtb 
infection, B cells are able to influence the host immune response and disease 
outcome by engaging the Fc receptors and influencing the Th1 activation and 
containment on the mycobacteria (22). 




1.3.2.2. Cell mediated response 
 
1.3.2.2.1. T cells 
 
T cells are the primary cells involved in the cell mediated immune response, 
however, they are not the only cells involved. Two of the important T cell subsets are 
the T cytotoxic cell (CD8+ T cells) and the T helper cells (CD4+ T cells). The T 
helper cells secrete mediators such as cytokines which direct the functioning of other 
T cells, B cells and other phagocytic cells to perform their function.  T cytotoxic cells 
will directly bind to and kill the pathogens involved or the infected cells.  APCs ingest 
and package the pathogens and display them as antigens on their surface. MHC I 
molecules present antigen from the cytosolic compartment (produced within the cell, 
i.e. viral particles) to CD8+ cytotoxic T cells, which will destroy the infected cells. 
MHC II molecules present antigens that have entered the host cell via the endocytic 
pathway (i.e. through phagocytosis) to T cells, which will subsequently become 
activated and proliferate. The T helper cells then release cytokines, which activate 
the antigen presenting cell (i.e. the macrophage to improve its killing function of 
phagocytosed pathogens) or which will stimulate the B cells to produce antibodies 
(23).  
 
1.3.2.2.1.1. CD4+ T helper cells 
 
Once a pathogen has been recognised as such and phagocytosed by APC’s, the 
cells travel to the lymphoid organs where they package and display the pathogens 
antigens on the surface of the cell via the MHC II molecule. Naïve T helper cells 
recognise and respond to the antigens by becoming activated, by differentiating and 
by proliferating (clonal expansion).  Some of the CD4+ T cells will differentiate into 
effector cells and be able to secrete different cytokines that can perform different 
functions. T cell phenotypes include but are not limited to Th1, Th2, T regulatory 
(Treg), T follicular (Tfh) and Th17.  During the initial activation of the naïve cells, a 
subset of long-lived memory cells is also formed. These memory cells can remain in 
the body for a number of years and are specific for the antigen it has just 




encountered. These cells have the advantage of being able to respond much faster 
and more efficiently upon re-exposure to the pathogen (23) 
 
1.3.2.2.1.2. CD4+ effector T cells 
 
These perform their function by differentiating into a type of T helper (Th) cell which 
results in the secretion of a group of cytokines which can provide assistance to other 
cells to perform different functions. A big factor in the determination of a T helper cell 
group and subsequently the secretion of a cytokine group is based on the status of 
cytokines in the environment at the time of the encounter.  The five dominant 
lineages of T helper cells which are produced are Th1, Th2 and Th17, T follicular 
cells (TFH) and T regulatory (Tregs) cells (Figure 1.2). Each type of cell produces a 
different group of cytokines which results in a different function  (24).  CD4+ T cells 
play critical roles in mediating adaptive immunity to a variety of pathogens. They are 
also involved in autoimmunity, asthma, and allergic responses as well as in tumour 
immunity. During TCR activation in a particular cytokine milieu, naive CD4 T cells 
may differentiate into one of several lineages of T helper (Th) cells, including Th1, 
Th2, Th17, and iTreg, as defined by their pattern of cytokine production and function 
(13).  The T helper cell phenotypes will be discussed under the adaptive immune 
response. 
 
1.3.2.2.1.3. CD8+ cytotoxic T cells 
 
Pathogen proteins and their peptides that are present in the cytoplasm of a cell will 
be processed by the proteosome and transported into the endoplasmic reticulum via 
the transporter associated with antigen processing (TAP) where it will eventually be 
displayed on the surface of the cell via MHC I molecule, resulting in recognition by 
naïve CD8+ T cells, followed by activation and clonal expansion of the CD8+ T cells 
(25).  CD8+ cytotoxic cells can directly kill the infected cells by releasing perforin and 
granulysin, which lyses host cells and induces apoptosis.  A subset of memory cells 
forms in much the same way as in CD4+ T cells and play a role during reinfection 
(23). 
 




1.3.2.2.2. T helper cell phenotypes (Figure 1.2) 
 
1.3.2.2.2.1. T helper 1 (Th1)  
 
Th1 cells are known as the principal regulators of type 1 immunity and  produce  the 
pro-inflammatory cytokines IFN-γ, IL-2, TNF-a and IL-12. The general consensus is 
that the CD4+ Th1 phenotype is characterised by the expression of CXCR3 and 
CCR5 (26).  
 
 IFN-γ: This is the most important cytokine involved in the immune response to 
Mtb infection.  IFN-γ is a pro-inflammatory cytokine and is predominantly 
secreted by CD4+ helper cells, CD8+ cytotoxic T cells and NK cells although 
there are other cells that may also contribute to its secretion. The main function of 
IFN-γ is the activation of macrophages as well as the promotion of Th1 response 
(27). Previous studies show that patients with a defect in IFN-γ production are 
prone to uncontrolled Mtb infections, poor granuloma formation and severe 
progression of disease (28). Patients with HIV are more susceptible to Mtb and 
this may be due to failure to produce sufficient levels of IFN-γ in the lung (21). 
 IL-2: Upon antigen presentation increased expression of the IL-2 receptor permits 
a rapid and selective expansion of CD4+ and CD8+ T cells.  Conversely it has 
been shown that IL-2 also plays a role in down-regulating the immune response 
in the prevention of autoimmune diseases (29). 
 TNF-α: Plays an important role in recruitment of leukocytes to the site of infection 
and granuloma formation and maintenance. It has been reported that mice that 
are deficient in TNF-α are unable to form proper granulomas (30).  TNF-α is also 
instrumental in the activation of macrophages as well as stimulating apoptosis 
and reactive oxygen (ROI) and nitrogen intermediates (RNI) (21).  While TNF-α is 
vital in the containment of Mtb, it has also been identified as a main player in the 
destruction of lung tissue due to the chronic inflammation and necrosis (31).  The 
characteristic fever and wasting that is commonly seen in patients with Mtb can 
be partially attributed to TNF-α production. 




 IL-12: IL-12 is important in the polarisation of Th1 cells and the induction of IFN-γ 
production. IL-12 also stimulates the proliferation of antigen-specific cytolytic T 
cells and NK cells thereby enhancing cytotoxicity (21). 
 Lymphotoxin-α (LT- α): LT- α is primarily produced by activated T cells, B cells 
and NK cells and is known to mediate some important functions of the immune 
system such as the development of lymph nodes, Peyer’s patches and primary B 
cell follicles (32).  Allie et al (2010) demonstrated that LT- α deficient mice were 
highly susceptible to Mtb despite their ability to still mount a Th1 response. These 
mice had uncontrolled bacterial growth with a lack of well demarcated primary 
granuloma formation similar to that seen in TNF-α deficient mice (32). 
 
1.3.2.2.2.2. T helper 2 (Th2) 
 
The primary cytokine is IL-4 with IL-5, IL-10 and IL-13 making up the rest of the 
signature cytokine profile. Th2 cells have also been found to produce IL-9 and TNF-α 
but not IFN-γ. It is accepted that the surface expression of Crth2 (Chemo-attractant 
receptor-homologous molecule expressed on Th2 cells), CCR3 and CCR4 denote a 
Th2 subset (26).  
 
 IL-4: IL-4 is elevated in active disease and has been shown to have a pathogenic 
role during the late phase of Mtb infection.  IL-4 down-regulates the Th1 
responses and a high expression of IL-4 has been associated with cavitation (21). 
 IL-5: IL-5 promotes the differentiation and activation of eosinophils in the bone 
marrow (33). 
 IL-9: IL-9 promotes the expansion of mast cells especially in allergic responses 
and lung inflammation (34). 
 IL-10: IL-10 is a powerful immunosuppressive cytokine that affects macrophages, 
monocytes, DC’s and T cells.  Its function stretches from deactivation of 
macrophages and reduced Th1 response to decreasing reactive oxygen 
intermediates (ROI) and reactive nitrogen intermediates (RNI) and also limiting 
antigen presentation, all which may have big effects on the innate and adaptive 
immune response in TB. IL-10 is thought to be an important biomarker of disease 
progression in TB and a correlate of susceptibility to TB (35).  




 IL-13: IL-13 is involved in allergic responses and IgE synthesis and contributes to 
airway inflammation (36). 
 
1.3.2.2.2.3. T helper 17 (Th17)  
 
These cells are derived from CD4+ naïve T cells, in an environment with TGF-β and 
IL-6, and are characterised by the production of IL-17a, IL-17f, IL-21 and IL-22. The 
cytokines mediate the host defensive mechanisms in various infections; however, 
these pro-inflammatory cytokines can cause immunopathology when the response is 
exaggerated.  There are few human studies on cytokines released by Th17 cells but 
mouse studies have shown that a high dose of Mtb delivered intratracheally was 
poorly controlled in the absence of IL-17 (37).  It has been determined that Th17 cells 
express CCR6 and CCR4 on their surface thus giving them a phenotype of co-
expression of CD4, CCR6 and CCR4 (38). 
 
1.3.2.2.2.4. T follicular cells (Tfh) 
 
Tfh cells are a subset of CD4+ T cells that reside in the secondary lymphoid tissues 
and function by providing assistance for B cell activation, expansion and 
differentiation (39).  The expression of CXCR5 with a concomitant loss of CCR7 
leads to the relocation of Tfh to B cell follicles (40).  The differentiation of Tfh relies on 
the transcription factor Bcl6 as a master regulator (41) and the primary cytokines that 
are produced during the induction of Tfh production are IL-6 and IL-21.  
 
1.3.2.2.2.5. T regulatory cells (Tregs) 
 
Tregs are a heterogeneous T cell population that are capable of suppressing the 
immune system and regulating self-tolerance.  Tregs are a critical component of 
immune cell homeostasis and function by enforcing a dominant negative regulation 
on other immune cells (42).  Singh et al. (2012) demonstrated that a high TB bacillary 
load correlated with increased Tregs which returned to normal levels after treatment 
indicating that expansion may occur in response to pathogen exposure (43). Natural 
Tregs emerge from the thymus as single CD4+ cells, which when stimulated by an 




antigen, differentiate into Tregs expressing CD25 and FoxP3. Thus it is widely 
accepted that the phenotype for Tregs is the co-expression of CD4, CD25hi and 








Figure 1.2: Illustration of the T helper cell phenotypes originating from naïve CD4+ T cells. 
A naïve CD4 T cell has the ability to give rise to different phenotypes of T cells namely Th1, Th2, 
Th17, Tfh and Treg cells. 
 
 




1.4. Cell surface markers  
 
A cell surface marker can be defined as a protein that is present on a cell and 
distinguishes it from other subsets of cells.  Clusters of differentiation (CD) provides 
a simple and unambiguous nomenclature system to be used in immune phenotyping 
by identifying subsets of cells based on their surface marker expression (45).  
Surface markers are able to differentiate between lineages of cells as well as stages 
in development, activation or proliferation of cells (46).  Specific cell surface markers 
can provide information on whether a cell type will respond to drugs or whether a cell 
expresses a receptor necessary for specific biological processes (47). 
 
1.5. Granuloma formation 
 
A granuloma is developed by the host as a way to contain or eliminate the pathogen 
however; it can also provide an environment in which the bacteria can survive for 
many years after infection. The formation of a granuloma starts shortly after 
inhalation of the Mtb bacillus which, once inhaled, travels to the alveoli and is 
phagocytosed by alveolar macrophages. The macrophages release cytokines and 
chemokines, attract additional monocyte-derived macrophages and neutrophils to 
the site of infection forming the start of the granuloma (48).  The centre of the 
granuloma is predominantly made up of infected macrophages surrounded by 
epitheloid cells and multinucleated giant cells. Once these cells have arranged 
themselves in an aggregate around the infected macrophages, lymphocytes create a 
rim around the granuloma followed by a fibrous capsule (21).  Over time the centre 
becomes necrotic and takes on a caseous appearance, which is thought to be 
hypoxic and may play a role in the Mtb metabolism, altering susceptibility to some 
anti-tuberculosis treatments (49). The cytokines IFN-γ and TNF-α are both important 
in the formation and maintenance of the granuloma while IL-10 has been shown to 








1.6. Methods of detection 
 
Current methods for diagnosis of TB include the following: 
 
1.6.1. Sputum smear microscopy 
 
Smears stained with carbol fuchsin and fluorochromes such as auramine-rhodamine 
are widely supported for diagnosis of Mtb in clinical samples (51).  
 
1.6.2. Sputum culture 
 
Different media used in culture methods include: 
 
I. Lowenstein-Jensen medium – egg based solid medium which may take 
between 4-6 weeks for a result. 
II. BACTEC liquid culture offers a more sensitive and rapid test to solid media 
with an available result within 1-3 weeks. 
III. Mycobacterial growth indicator tube (MGIT) is a liquid culture medium that is 
able to provide a result in as little as 8 days while simultaneously allowing for 
drug susceptibility by the addition of antibiotics.   
 
1.6.3. Nucleic acid amplification test (NAAT)  
 
NAAT’s are able to detect TB rapidly and with a high specificity by targeting specific 
nucleic acid sequences. A range of commercially available tests have been 
developed and have proved to increase sensitivity and specificity of both smear 
positive and smear negative samples (51). 
 
1.6.4. Drug resistance tests  
 
The emergence of multi-drug resistant (MDR) and extensive-drug resistant (XDR) 
strains of Mtb have increased the importance of drug susceptibility testing (DST) at 
diagnosis. Methods have been developed that simultaneously detect infection with 
Mtb and amplify regions of drug resistance.   
 




 Line probe assays (LiPAs): These use a technology where amplified DNA is 
applied to strips which contain probes specific for Isoniazid (INH) and Rifampin 
(RIF) resistance. 
 Molecular beacons: These are colorimetric based assays that provide an ease of 
assay interpretation.  DNA probes contain an intrinsic fluorophore which, when 
bound to its complementary sequence, undergo a conformational change and 
produce a visually detectable signal (51). One of these tests is the GeneXpert® 
which can simultaneously give an Mtb diagnosis while also testing for rifampicin 
resistance in approximately 2 hours. The reagents that are used are enclosed in 
a single cartridge and contain anti-tuberculosis properties which results in a safe 
and convenient form of diagnosis that can be performed outside of a laboratory 
(52) 
 
1.6.5. Interferon Gamma release assays (IGRA) 
 
IGRA is a blood-based assay that identifies an immune response to Mtb specific 
antigens (ESAT-6, CFP-10 and TB7.7) by measuring the presence of TB specific 
effector memory cells after exposure of an individual to TB. 
 
 QuantiFERON-TB Gold In-Tube assay (QFN-GIT):  IFN-γ is produced in 
response to stimulation with ESAT-6, CFP-10 and TB 7.7 and the concentrations 
are detected using an ELISA test.  
 T-SPOT. TB assay: T-SPOT. TB test measures the number of IFN-γ producing 
cells in response to ESAT-6 and CFP-10.  The principle of the T-SPOT. TB assay 
is based on the enzyme-linked immunosorbent spot assay (ELISPOT). 
 
1.7. Flow cytometry 
 
Flow cytometry refers to the measurement of a single cell as it passes through a 
region of investigation. It allows a single cell to be studied at a time with a flow rate of 
over 1000 cells (events) per second. The investigation of each cell is multi-
parametric and includes but is not limited to the following properties: 
 Size of the cell (forward scatter; FSC) 




 Internal integrity and granularity (side scatter; SSC) 
 Cell surface markers or proteins 
 Auto-fluorescence  
 
There are three main components of flow cytometry: 
 
 Fluidics system: Through hydrodynamic focusing, cells are separated and 
allowed to pass single file through one or more lasers.  
 
 Optics system: Once the cells have passed through the lasers, light is either 
scattered and collected in detectors or it excites fluorochromes and is collected in 
a photomultiplier tube (PMT).  Antibodies are directly conjugated to fluorescent 
dyes (fluorochromes) which, when passing through a laser, accepts light from a 
laser and is excited at a specific wavelength which is optimal to that dye.  During 
excitation electrons move from a resting state to an excited state and then back 
to a resting state. The result of this is an emission of light at a lower energy state 
which appears as a longer wavelength. It is this difference in the excitation and 
emission wavelengths that allows us to separate the light using detectors.  The 
laser is scattered when it strikes the cell and the scattered light is collected by a 
collection lens and focused to a photodiode where it is converted into a current 
and recorded by the electronic system. Light that is collected in the forward 
direction is used to determine the size of a cell (forward scatter) and light that is 
collected at 90 degrees indicates the granularity of the cell (side scatter). Emitted 
light is collected with a collection lens and directed towards a series of dichroic 
mirrors and filters until it reaches its designated PMT (53). 
 
 Electronics system: Once emitted light reaches its PMT it is converted into 
electrons. The electrons are multiplied in order to produce a voltage pulse by 
either linear or logarithmic amplifiers and analog digital converters. The voltage 
pulse is sent to the signal processors where it is measured for its height, width 
and area and is stored in the software for further analysis (53).  
 




1.8. FACSTM CAP Technology (CAP: Combinatorial Antibody Profile) 
 
With the continued and growing identification of cell surface markers using flow 
cytometry it became necessary to create a platform that allowed the characterisation 
of a heterogeneous population of cells, using many of the monoclonal antibodies 
available, simultaneously.  Becton Dickinson (BD) Biosciences developed the 
FACS™ CAP technology as a multi-dimensional screening tool for rapid 
identification and characterisation of human cell surface protein expression profiles 
using high throughput flow cytometry.  The antibody array panel includes a selection 
of 252 antibodies, directly conjugated to the fluorochromes FITC or Alexa488, PE 
and APC or Alexa647, placed in combinations of three antibodies in each well of a 
96 well plate.  Isotype controls are included in the plates to assess the amount of 
background staining and non-specific Fc receptor binding.  Staining of the cells 
occurs using an automated liquid handling system while a semi-automated flow 
cytometry system and software are used for the acquisition of the cells (54).  A 
standardised algorithm has been designed to analyse the flow cytometry data.  The 
antibodies present in the FACSTM CAP plates represent intercellular pathways, cell 
proliferation, cell-cell signalling, chemotaxis, apoptosis, cell adhesion and cell motility 
while also allowing for the addition of antibodies to monitor specific immune functions 
and inflammatory responses.  BD designed the FACSTM CAP technology to be a 
valuable tool in the use of stem cell therapy or cell banking by documenting 
phenotypic variants or changes due to different donors, evaluating isolation 
protocols, culture or storage media and studying stem cells for differentiation, 
carcinogenesis and drug targeting (54).  This technology can also be applied to a 
number of experiments involving cell surface proteins such as identifying a set of 
biomarkers that are present on one set of cells when compared with cells from 
another patient, time point or different culture conditions all of which would be highly 








1.9. Goals and objectives  
 
1.9.1. Context   
 
Evaluating the success of chemotherapy for tuberculosis (TB) currently relies on a 
battery of inadequate tests and new markers are urgently needed to facilitate the 
discovery and testing of new TB drugs. The hypothesis underlying this project is that 
the expression of surface markers on peripheral blood mononuclear cells (PBMCs) 
of TB patients, from pre-treatment and during standard anti-tuberculosis 
chemotherapy, will provide clinically valuable markers for diagnosis and early 
treatment response. This project is a sub-study, in collaboration with Becton 
Dickinson Technologies (BDT), of an on-going study funded by the Bill and Melinda 
Gates Foundation (BMGF) and led by the Catalysis Foundation for Health.  The goal 
of the main project was to identify biomarkers for bacterial load during active TB and 
during therapy.  Identification of load biomarkers would assist in the stratification of 
patients into different treatment arms, depending on their risk for poor outcomes.   A 
range of sample types (blood, breath condensate, saliva, sputum and urine) were 
obtained to search for such markers.   Patients also underwent three [18F]-fluoro-2-
deoxy-D-glucose positron emission tomography/computer tomography (FDG-
PET/CT) imaging studies to further define the extent of inflammation in the lungs and 
the changes during treatment.   
 
1.9.2. Project goal 
 
The goal of the FACSTM CAP project is to discover host candidate biomarkers for TB 
treatment response. These markers will be based on PBMC surface molecule 
expression in particular early treatment response and cure at the end of standard 
anti-TB therapy. The objective is to use the BDT developed FACSTM CAP technique 
to discover peripheral blood cell surface markers which can serve as indicators of TB 
disease status. 
  




1.9.3. Primary objectives 
 
1.9.3.1. Objective 1:  Optimization of FACSTM CAP procedures  
 
1.9.3.1.1. Objective 1.1: Assess the effect of cryopreservation on FACSTM CAP 
performance.  Cryopreservation serves as a useful tool for storing live 
cells for prolonged periods of time allowing retrospective phenotypic and 
functional analysis. The idea for this study was to use frozen PBMCs from 
TB patients that were previously prepared and frozen in liquid Nitrogen. 
 
1.9.3.1.2. Objective 1.2:  Assess the effect of PBMC culture in the presence of Mtb 
antigen stimulation on marker expression in comparison to unstimulated 
PBMCs.  This experiment would help determine if by inducing TB specific 
antigen we would have greater chance of finding variation in the 
expression of these antigens during the course of therapy. 
 
 
1.9.3.2. Objective 2: To assess the differential PBMC surface marker 












Chapter 2:   Materials and methods 
 
2.1. Recruitment of patients 
 
Patients were recruited from four local communities in Cape Town, South Africa, 
namely Ravensmead, Uitsig, Adriaanse and Elsiesriver all of which have a high 
prevalence of TB and a low incidence of HIV.  
 
2.1.1. Inclusion criteria 
 
 All patients had to be between the ages of 16 and 70 years.  
 Willing to give informed consent. 
 Willing to be tested for HIV and have their results disclosed to the field worker. 
 TB patients had to have a newly confirmed diagnosis of pulmonary TB infection 
or a recurrent infection at least 12 months after completing the previous 
treatment. TB was confirmed by GeneXpert® (Cepheid) testing and MGIT culture 
on suspected patients. Positive cultures were confirmed to be due to Mtb by acid-
fast bacilli (AFB) staining, followed by Polymerase chain reaction (PCR, an in-
house assay for RD1, RD4, RD9 and RD12) or the Capilia TB assay. 
 Healthy community controls had to have a negative sputum GeneXpert® test 
taken at recruitment into the study. 
 Other lung disease controls (OLD) had to have a negative sputum GeneXpert® 
test at recruitment as well as a diagnosis of one of the following: 
 
- febrile illness with chest symptoms 
- radiographic evidence of viral or bacterial pneumonia 
- bronchiectasis with acute exacerbation 









2.1.2. Exclusion criteria 
 
 People with a haemoglobin level of <10g/l. 
 Medical conditions such as Diabetes Mellitus, chronic 
bronchitis/asthma/emphysema requiring steroid treatment, cancer, pregnancy or 
steroid treatment within the last 6 months.  
 People without a permanent residence or residence in the study area for less 
than 3 months.  
 Participation in a drug or vaccine trial. 
 Alcohol abuse or the use of illicit drugs. 
 TB patients who had started treatment prior to enrolment were excluded.  
 Healthy community controls who had suffered with an acute respiratory infection 
within the last four weeks.  
 Other lung disease controls were excluded if their GeneXpert® test proved to be 
positive for Mtb. 
 
Patients who successfully enrolled in the study made themselves available to have 
blood drawn at multiple time points. The blood sampling for this study occurred at 
diagnosis (Dx), 4 weeks after commencement of treatment (Week 4) and at the end 
of treatment (Week 24, EOT). 
 
In total 48 TB patients were enrolled for this study.  Nine patients were dropped from 
the study for reasons such as pregnancy, conversion to positive HIV status and 
insufficient cell concentration for plate preparation. Six other patients were dropped 
for incomplete data due to missed clinic visits or instrument error resulting in poor 
quality flow cytometry data. In total 33 TB patients, with complete data for three time 
points, were included for data analysis (S112, S123, S124, S125, S129, S130, S131, 
S132, S133, S134, S136, S137, S138, S139, S140, S141, S142, S144, S145, S146, 
S147, S149, S150, S153, S154, S155, S156, S163, S164, S167, S168, S169, 
S170).   
 
Control groups were represented by 14 healthy community controls and 10 patients 
with other lung diseases (OLD). Only 11 healthy controls (S148, S157, S158, S179, 
S180, S181, S182, S194, S195, S197, S198) and 9 patients with OLD (S166, S173, 




S175, S177, S184, S186, S187, S188, S189) were analysed due to time constraints.  

























S112 M 52 Active TB and cavities in right lung Y 4 Positive Active TB Negative Definite cure 
S123 M 40 In keeping with Active TB Y 5 Positive Active TB Positive Definite cure 
S124 M 24 Active TB Y 5 Positive Active TB Negative Definite cure 
S125 M 32 Active TB. No clear cavity Y 8 Positive Active TB Positive Probable cure 
S129 M 40 Consistant with active PTB N 4 Positive Active TB Negative Definite cure 
S130 M 29 Compatible with TB N 6 Positive Active TB Negative Definite cure 
S131 F 18 Abnormalities consistent with Active 
TB 
Y 14 Positive Active TB Negative Definite cure 
S132 F 17 Abnormalities consistent with Active 
TB 
Y 5 Positive Active TB Positive Definite cure 
S133 F 33 Abnormalities consistent with Active 
TB 
Y 6 Positive Active TB Inconclusive Definite cure 
S134 F 24 Abnormalities consistent with Active 
TB 
N 3 Positive Active TB Negative Definite cure 
S136 M 42 Consistent with Previous TB and 
possible New Activation. 
Y 18 Positive Active TB Negative Probable cure 
S137 F 44 Extensive Active TB Y 7 Positive Active TB Negative Definite cure 
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Table 2.1: Patient demographics - TB patients continued 
S138 M 23 Extensive Active TB Y 4 Positive Active TB Negative Definite cure 
S139 M 38 Abnormalities consistent with Active 
TB 
Y 5 Positive Active TB Positive Definite cure 
S140 M 22 Abnormalities consistent with Active 
TB 
Y 6 Positive Active TB Positive Definite cure 
S141 M 17 Abnormalities consistent with Active 
TB 
Y 10 Positive Active TB Negative Definite cure 
S142 F 43 Abnormalities consistent with Active 
TB 
N 3 Positive Active TB Positive Definite cure 
S144 M 31 Abnormalities consistent with Active 
TB 
N 7 Positive Active TB Positive Definite cure 
S145 F 19 Abnormalities consistent with Active 
TB 
Y 4 Positive Active TB Negative Definite cure 
S146 M 20 Abnormalities consistent with Active 
TB 
N 8 Positive Active TB Negative Definite cure 
S147 M 23 Active Bilateral TB N 5 Positive Active TB Inconclusive Definite cure 
S149 F 19 Abnormalities consistent with Active 
TB 
N 3 Positive Active TB Positive Definite cure 
S150 F 21 Active TB with slight involvement Y 6 Positive Active TB Negative Probable cure 
S153 M 25 Abnormalities consistent with Active 
TB 
Y 5 Positive Active TB Positive Definite cure 
S154 F 42 Active TB bilateral upper zones Y 4 Positive Active TB Positive Definite cure 
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Table 2.1: Patient demographics - TB patients continued   
S155 F 36 Active TB in Left Upper Lobe Y 8 Positive Active TB Negative Definite cure 
S156 M 64 Active TB in Bilateral Upper Lobes Y 3 Positive Active TB Positive Definite cure 
S163 M 25 Active TB in left lung N 4 Positive Active TB Positive Not cured 
S164 M 45 Abnormalities consistent with Active 
TB 
N Neg ** not done Active TB Negative Definite cure 
S167 M 41 Active TB left lung N 4 Positive Active TB Negative Definite cure 
S168 F 23 Bilateral Active TB N 4 Positive Active TB Negative Not cured 
S169 M 30 Right lung active TB and Pleural 
effusion 
N 4 Positive Active TB Negative Not cured 
S170 M 30 Extensive bilateral active TB Y 6 Positive Active TB Negative Probable Cure 
S191 F 50 Not done N 9 Positive Active TB Not applicable Not applicable 
S192 F 47 Not done N 20 Positive Active TB Not applicable Not applicable 
S193 F 52 Not done N 3 Positive Active TB Not applicable Not applicable 
S201 F 41 Not done Y 5 Positive Active TB Not applicable Not applicable 
S203 F 36 Not done N 9 Positive Active TB Not applicable Not applicable 
** Patient S164 was treated as a TB positive patient due to a positive GeneXpert
®
 test performed at the National Health Laboratory Service.  We were unable 
to obtain a positive culture result using the research sputum sample. 
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TTP (days) Speciation Status 
S166 M 31 Right middle lobe collapse; 
consolidation 
Negative Y Negative Not done OLD  
(pneumonia) 
S173 F 62 Bilateral disease, not in keeping 
with TB 
Negative N Negative Not done OLD  
(pneumonia) 
S175 M 49 Mild bilateral bronchiectatic 
changes 
Positive N Negative Not done OLD  
(pneumonia secondary 
to bronchiectasis) 
S176 F 40 Normal examination Negative N Negative Not done OLD  
(upper respiratory tract 
infection) 
S177 F 28 Infiltrates in right lower lobe. Positive N Contaminated Negative OLD 
 (pneumonia) 
S184 M 34 Cardiomegaly and patchy 
consolidation in RUL and RLL 
Positive Y Contaminated Negative OLD  
(pneumonia) 
S186 F 31 Left lower lobe consolidation 
 
Positive Y Negative Not done OLD 
 (Pneumonia) 
S187 M 23 Left lower lobe pneumonic 
consolidation and pleural effusion 
Positive Y Negative Not done OLD 
 (pneumonia) 
S188 M 39 Large left effusion 
 
Positive Y Contaminated Negative OLD  
(parapneumonic 
effusion) 
S190 F 52 Abnormalities in keeping with 
pneumonia 
 
Positive Y Negative Negative OLD 
 (pneumonia) 
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TTP (days) Speciation Status 
S148 M 21 Positive Y Negative Not applicable Healthy control 
S157 M 25 Positive Y Contaminated Negative Healthy control 
S158 F 23 Positive Y Negative Negative Healthy control 
S179 F 34 Positive Y Negative Negative Healthy control 
S180 M 26 Negative N Contaminated Negative Healthy control 
S181 M 27 Negative Y Negative Not applicable Healthy control 
S182 M 27 Negative Y Negative Not applicable Healthy control 
S194 F 30 Negative N Negative Not applicable Healthy control 
S195 M 25 Positive Y Negative Not applicable Healthy control 
S197 F 30 Positive Y Negative Not applicable Healthy control 
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2.2.1. FACS CAP lyoplates 
 
FACSTM CAP lyoplates were manufactured by BD Technologies in North Carolina and 
BD Biosciences in California. Seventy nine combinations of three antibodies were 
prepared in tubes at the correct concentrations at BD Technologies, North Carolina 
(NC) and sent to California.  A master plate was created using the combinations from 
the tubes prepared in NC, from which 500 daughter plates were produced.  Due to the 
high risk for inter-plate variability, the final daughter lyoplates were produced using an 
automated system and lyophilised to increase stability and ease of transport and 
storage. For each lot, a number of plates were used for quality control purposes and 
upon passing the quality control check, were sealed in foil pouches, assigned a lot 
number and given an expiry date of two years after production.  Antibodies used in the 
FACSTM CAP lyoplates were directly conjugated to fluorescent dyes detectable in 
channels 1, 2 and 4 on the FACSCaliburTM (Table 2.4).  Although there are a total of 
252 antibodies in each plate (Table 2.5), some were used more than once or multiple 
times to verify accuracy of pipetting and reproducibility between wells.  
 
 
Table 2.4: List of fluorescent dyes directly conjugated to antibodies in the FACS
TM
 CAP plates 
 
 
Fluorochrome Abbreviation Detector channel 
Fluorescein isothiocyanate FITC FL1 
Alexa Fluor 488 Alexa488 FL1 
R-phycoerythrin PE FL2 
Allophycocyanin APC FL4 
Alexa Fluor 647 Alexa647 FL4 




Table 2.5: List of antibodies included in the FACS
TM
 CAP plates 14 
 
CD1a CD11c CD27 CD41b CD49d CD62P CD80 CD102 CD119 CD140b CD172a CD220 CD294 CXCR2 MET 
CD1b CD13 CD28 CD42a CD49e CD63 CD81 CD103 CD120b CD141 CD172b CD221 CD318 CXCR5 MIC A/B 
CD1d CD14 CD29 CD42b CD49f CD64 CD85 CD104 CD122 CD142 CD178 CD226 CD326 EGFR NKB1 
CD2 CD15 CD30 CD43 CD50 CD66 CD86 CD105 CD123 CD146 CD180 CD227 CDw329 F11 R NKG2D 
CD3 CD16 CD31 CD44 CD51 CD66b CD87 CD106 CD124 CD147 CD181 CD231 CD336 FGFR3 NKp46 
CD4 CD16b CD32 CD45 CD53 CD69 CD88 CD107a CD126 CD150 CD183 CD235a CD337 FMC7 PAC-1 




CD5 CD19 CD34 CD45RB CD55 CD71 CD90 CD108 CD130 CD154 CD195 CD252 CCR1 HER-2/neu 
P-
glycoprotein 
CD6 CD20 CD35 CD45RO CD56 CD72 CD91 CD109 CD132 CD158a CD200 CD256 CCR2 HLA-A,B,C SSEA3 
CD7 CD21 CD36 CD46 CD57 CD73 CDw93 CD110 CD133 CD158b CD201 CD267 CCR3 HLA-DR SSEA4 
CD8 CD22 CD37 CD47 CD58 CD74 CD94 CD112 CD134 CD161 CD205 CD268 CCR4 Integrin b7 TGFBR2 
CD9 CD23 CD38 CD48 CD59 CD75 CD95 CD114 CD135 CD162 CD206 CD271 CCR6 KDR TNF 
CD10 CD24 CD39 CD49a CD61 CD77 CD97 CD116 CD137 CD163 CD208 CD275 CCR7 LAIR1 
TRA-1-60 
antigen 
CD11a CD25 CD40 CD49b CD62E CD79a CD98 CD117 CD138 CD164 CD210 CD278 CCR8 Le B4 R 
TRA-1-81 
antigen 








Wells A01 – A03 of the FACSTM CAP plates were left empty to allow for the addition of 
unstained cells for instrument setup. Wells A04 – A08 were also left empty for the 
addition of unstained cells and single antibody to be used for post-acquisition 
compensation. Wells B01 – B05 contained isotype controls relevant to each of the 
classes of antibodies used throughout the plate.  Wells B06 – H12 contained the three-
colour antibody cocktails 
 
2.2.2. Additional reagents 
 
Table 2.6 lists the additional reagents necessary for cell preparation, plate preparation 






















Table 2.6: List of additional reagents 
Reagent name Catalogue number Manufacturer 
Phosphate buffered saline BE17-517Q Whitehead Scientific 
Ficoll-paque 17-1440-03 GE Healthcare Life Sciences 
Human FcR Blocking 
reagent 
130-059-901 Miltenyi Biotec 
Fetal bovine serum de14-801fi Whitehead Scientific 
Staining buffer PBS with 1% FBS N/A 
BD FACSTM CAP lyoplates N/A Becton Dickinson 
Anti-CD45 FITC  340664 Becton Dickinson 
Anti-CD45 PE 555483 Becton Dickinson 
Anti-CD45 APC 340943 Becton Dickinson 
Anti-CD8 FITC 555634 Becton Dickinson 
Anti-CD4 PE 555347 Becton Dickinson 
Anti-CD3 Alexa 647 557706 Becton Dickinson 
BD calibrate 3 beads 340486 Becton Dickinson 
BD APC calibrate beads 340487 Becton Dickinson 
16% Paraformaldehyde 19943 LT Thermo scientific 
Tuberculin PPD 2390 Staten Serum Institute 
DMSO D8418 Sigma Aldrich 
Trypan Blue 93595 Sigma Aldrich 
AIM media 12055091 Life Technologies 
Greiner 50mL centrifuge tube PGRE227261 Lasec 
Pasteur pipette 3mL PLPS135138 Lasec 
Cryovials, 2mL PAXGCRYO-2ML-RB-C Lasec 
P1000 sterile pipette tips FA111-NXL-1000 WhiteSci 
P200 sterile pipette tips FA108-200 WhiteSci 
Disposable 25mL pipette PLPS162510 Lasec 
Disposable 10mL pipette PGRE607160 Lasec 
0,6mL conical tubes PAXGMCT-060-C Lasec 




2.3. Laboratory Methods 
 
2.3.1. Sample preparation and cell staining 
 
Peripheral blood mononuclear cells (PBMC’s) were isolated from the anti-coagulated 
blood, stained with fluorescent labelled antibodies and data acquired by the 
FACSCaliburTM. 
 
2.3.1.1. Sample collection 
 
Each blood draw consisted of approximately 54mL of blood collected into sodium 
heparin tubes. The tubes were inverted 10 times after venepuncture to ensure the 
anticoagulant was mixed sufficiently with the blood and preventing the formation of 
fibrin clots.   
 
2.3.1.2. PBMC preparation 
 
Whole blood was diluted 1:1 with 1 x phosphate buffered saline (PBS) and the 
diluted blood was layered onto Ficoll in a 50mL disposable tube. The 50mL tubes 
were centrifuged at 400 relative centrifugal forces (RCF) for 25 minutes with the 
brake and acceleration on the minimum setting. After centrifugation the PBMC’s 
were easily visualised due to the density gradient layers. Red cells sediment at the 
bottom of the tube, followed by the layer of Ficoll, a thin band of PBMC’s and finally 
the bulk is made up of plasma and PBS. The PBMC’s were easily obtained by 
discarding the plasma/PBS layer until approximately 1 cm above the PBMC layer. 
Using a Pasteur pipette, the PBMC’s were removed, along with a small amount of 
Ficoll, and placed in a clean 50mL tube. This was done for each tube and the cells 
were collected in one 50mL tube. The tube was filled up to 50mL with clean PBS and 
centrifuged for 10 minutes at 400 RCF (wash step 1). After the wash step, the 
supernatant was discarded and the pellet re-suspended in 5mL dH2O to lyse the 
remaining red blood cells. After swirling the tube 10 times, PBS was added to a total 
volume of 20mL and the tube was centrifuged at 400 RCF for 10 minutes (wash step 
2). The supernatant was discarded and the pellet was re-suspended in 5mL PBS 




using a Gilson P1000 pipette. Counting of the PBMC’s was performed by mixing 
10µL of the cell suspension with 40µL of Trypan Blue and placing 10µL of the 
solution into a haemocytometer. The cell count was performed and reported as total 
cell count using the following calculation: 
 
(Cell count X dilution factor in Trypan Blue X 10000) (Volume of cells) 
= (Cell count X 50000) (5) 
 
The remainder of the cell suspension was brought to a volume of 15mL by adding 
PBS and centrifuging at 400 RCF for 10 minutes. The cells were diluted to a 
concentration of 1 X 107 cells/mL in staining buffer composed of 1% fetal bovine 
serum (FBS) in phosphate buffered saline (PBS). FcR blocking reagent was added 
at a concentration of 20µL per 1 X 107 cells/mL and incubated for 10 minutes, 
followed by a wash step with PBS.  After centrifugation at 400RCF for 8 minutes, the 
supernatant was discarded and the cells were diluted to a concentration of 1 X 106 
cells/mL. A minimum of 20mL of cell suspension was needed which in some cases 
required a cell concentration of less than 1 X 106 cells/mL however this was not a 
frequent occurrence. The cell suspension was passed through a 70µm cell strainer 
to remove clumps of cells and debris and prevent blockages of the instrument during 
acquisition. 
 
2.3.1.3. Cryopreservation of PBMCs 
 
Five healthy participants were recruited to compare the effects of cryopreservation 
on the expression of surface markers on PBMC’s.  Upon receiving the blood, PBMC 
isolation was performed as outlined previously. Once the protocol reached the 
second wash step, the samples were split in half. One half of the cells continued with 
the protocol as described above (section 2.3.1.2) while the other half was 
cryopreserved, to be processed at a later stage. Cryopreservation occurred as 
follows: 
The cryomedia of choice was 10% DMSO in 90% FBS and this was achieved by 
mixing 0.4mL of DMSO in 3.6mL of heat inactivated FBS. The cryomedia was placed 
on ice until the cells were ready for cryopreservation. After the second wash step of 




the cells with PBS, 4mL of cryomedia was added to the cells drop by drop, while 
mixing, until the entire volume was added.  A cell count was performed to determine 
the number of cells that would be cryopreserved. This was done by using 10µL of 
cells from the cryomedia suspension and mixing it with 40µL of Trypan blue stain. 
Counting commenced as detailed previously and the calculation was performed as 
follows: 
 
(Cell count X dilution factor in Trypan Blue X 10000) (Volume of cells) 
= (Cell count X 50000) (4) 
 
The samples were split into two cryovials with 2mL’s each and placed into a Nalgene 
Mr Frosty® to be step-frozen overnight at -80°C. The next morning, the cells were 
placed into liquid nitrogen to be stored until use. After 4-8 weeks, the cells were 
thawed quickly in pre-warmed media, washed and the protocol continued as for fresh 
cells after the second wash with PBS.  
 
2.3.1.4. PPD stimulation of PBMCs 
 
Samples collected from five actively infected TB patients were used to determine if 
there was a change in expression of surface markers of purified protein derivative 
(PPD) stimulated PBMC’s. Upon receiving the blood, PBMC isolation was performed 
as outlined previously. Once the protocol reached the second wash step, the 
samples were split in half. The protocol as described above (section 2.3.1.2)  was 
continued with one half of the cells while the other half was re-suspended in AIM 
media at a concentration of 1 X 106 cells/mL.  The stimulant of choice was PPD at a 
concentration of 10µg/mL. The cells were incubated overnight at 37°C, 5% CO2. The 
following morning the cells were washed twice in PBS and the protocol was 
continued as described above.  
 




2.3.1.5. Staining of cells in FACSTM CAP plates 
 
Duplicate lyoplates were prepared for each sample in case of instrument or operator 
error. A volume of 100µL was added to each well of each lyoplate resulting in a 
concentration of 1 X 105 cells in each well. Wells A04 – A08 were stained as follows 
to allow for single stains to be used for post-acquisition compensation (Figure 2.1):  
 A04 – Unstained cells 
 A05 – CD45 FITC 
 A06 – CD45 PE 
 A07 – CD45 APC 
 A08 - CD4 PE, CD8 FITC, CD3 Alexa Fluor 647 
 
Wells A01 – A03 were left as unlabelled cells and were used to verify the setup of 
the instrument detectors between the tube and plate acquisition mode.  Wells A09 – 
A12 were left unlabelled as additional setup wells in case of an instrument problem 
or error (Figure 2.1).  At the same time, a tube with 1mL of PBMC’s was prepared to 
be used to set up the instrument prior to loading the plates. The cells were mixed 
using a multichannel pipette to ensure even and adequate mixing of the cells with 
the labelled antibodies.  The plates were incubated for 30 minutes in the dark.  A 
wash step was performed by adding 100uL of PBS to each well and 1 mL PBS to the 
tube containing unlabelled cells and centrifuged at 1200rpm for 8 minutes. The 
supernatant was discarded and the wash step was repeated with 200µL of PBS per 
well and 1mL per tube. After the second wash, 200µL of a 2% paraformaldehyde 
solution was added to each well and 1 mL to the tube and the plates and tube were 















CAP lyoplate layout 
Wells A01 – A03 contained unlabelled cells for instrument setup. A04 – A08 were used for single 
stains for post-acquisition compensation. Wells B01-H12 contained a three-antibody cocktail re-






A FACSCaliburTM with the addition of the High Throughput System (HTS) capable of 
handling 96 well plates was used for sample acquisition.  The FACSCaliburTM is a 
four colour flow cytometer fitted with an air-cooled argon laser which reads at 488nm 
and a red diode laser that reads at 633 nm.  It also contains the appropriate filters for 
detection of the fluorochromes FITC, Alexa Fluor 488, PE, APC and Alexa Fluor 647.  
The software that was used for setup and acquisition of the samples in tube mode 
was CellQuest™ Pro while the software used for the HTS loader was BD™ Plate 
Manager software.   The instrument and HTS loader were manufactured and 
































    
B             
C             
D             
E             
F             
G             
H             
Lyophilized antibodies B01 to H12 
B01 – B05 Isotype controls 
B06 – H12 Three-colour cocktail 
 




2.5. Acquisition of lyoplates on FACSCaliburTM 
 
After an overnight incubation the plates were acquired on the FACSCaliburTM as 
mentioned above (section 2.4). All samples were acquired uncompensated as post-
acquisition compensation was performed using third party software. Prior to the plate 
being loaded, a tube with unlabelled cells was loaded and acquired and used to set 
the voltages on each detector. The forward scatter (FSC) and side scatter (SSC) 
voltages were set such that the lymphocyte population was placed towards the 
junction of the X and Y axis (Figure. 2.2) to allow space for the granulocyte and 
monocyte population to fall within the plot. The voltage for each fluorescent detector 
was adjusted to ensure that the histogram plot fell within the first log decade while 
still allowing visualisation of the incline of the histogram plot. Once satisfactory 
settings were obtained, the settings were saved to each patient’s folder and identical 
settings were used for each of the duplicate plates.  Each well was mixed prior to 
acquisition and a volume of 100µL was acquired at a rate of 2µL per second. 
Acquisition was complete once 30 000 events had been acquired or once the 
acquired volume was depleted. 
Correct operation of the instrument was ensured by using FACS Calibrite beads 
before each run and maintenance was performed on a regular basis. 
 
The instrument settings are set to ensure clear lymphocyte, monocyte and granulocyte populations 
are evident. 
Figure 2.2: Demonstration of FSC and SSC settings during instrument setup. 




2.6. Data analysis 
 
The software used for analysis of this project is FlowJo version 7.6.5 (Tree Star Inc., 
Ashland, OR).  As the plates were acquired uncompensated, it was necessary to 
perform post-acquisition compensation on each plate to be used for analysis. Each 
sample was prepared in duplicate plates, therefore it was required to first verify the 
quality of the acquired data for each plate and to make a decision on which of the 
two plates would be used for analysis. This decision was based on whether or not 
the required amount of 30 000 events was reached and if there was an instrument 
error or blockage that resulted in a shift of the population to a point on the graph 
where it could not be gated accurately (Figure 2.3).  At times this required combining 
wells from plate 1 and plate 2 to have a full set of satisfactory data. Once the best 












There is no clear separation of cell populations with the majority of cells accumulating at the origin of 
the graph.  The lymphocytes cannot to accurately gated therefore this well would be eliminated from 
analysis. 
Figure 2.3: Graph demonstrating the effect of an injection probe blockage during acquisition. 




2.6.1. Post-acquisition compensation of flow cytometry data 
 
A plot of FSC vs. SSC was used to visualise the total cell population and a gate was 
set around the lymphocyte population (Figure 2.4A).  The gated cells were viewed 
using a plot of histogram vs. FL detector.  The negative expression population was 
visualised (Figure 2.4B) and the positive signals in the FL1 (well A05), FL2 (well 
A06) and FL4 (well A07) detectors were demarcated (Figure 2.4C). The 
compensation matrix was created by assigning the negative (unstained) population 
from well 04 as a universal negative control and the positive population from each 
channel.  The matrix was saved and assigned to the group of samples.  Well A08 
had a cocktail of three antibodies (CD4 PE, CD8 FITC and CD3 Alexa Fluor-647), 
one for each detector, and this well was used to verify the compensation was correct 














































Graph demonstrating the lymphocyte gate used for post-acquisition compensation (a).  Histogram vs 
FL1 detector of the gated lymphocyte population demonstrating the negative (b) and positive (c) 
expression populations.  Well A08 demonstrating correct post-acquisition compensation using the 




Figure 2.4: Demonstration of the steps involved in post-acquisition compensation. 
 




2.6.2. Analysis of flow cytometry data 
 
Isotype controls were included as negative controls to be compared against the 
sample wells to detect a positive signal. As there were two isotype controls for both 
FL1 and FL4 channels, it was necessary to determine the best control to use going 
forward. In most cases there was very little difference between them in which case 
the first control in each channel was used. Once the isotype control was chosen, the 
positive population gate was set so that when overlayed with the sample wells, 














Any expression that falls within the demarcated range is considered as positive.  This range was 
adjusted, based on the dot plot adjustments, if there was a shift in the expression and the 
demarcation between a positive and negative population was adjusted. 
 
 
Figure 2.5: Graph demonstrating the positive gate set on the isotype control. 
 




Once the gate was determined for all three channels, it was applied to all sample 
wells.  In the layout editor each channel was assigned a page on which the isotype 
histogram vs FL detector was placed. This was done 79 times for each channel, 
once for each well.  Starting with the first antibody cocktail well, B06, each sample 
was overlayed onto the isotype control which resulted in a representation of a 
positive expression population when compared with the negative expression 
population defined by the isotype control. The positive expression population was 
denoted by a percentage of the total events which was automatically saved in the 
statistics of the software (Figure 2.6).  
      
 
 










The isotype control (red) denotes a negative expression and is used to differentiate between a sample 
well (blue) with a negative (a) or a positive (b) expression. 
 
Figure 2.6: Demonstration of a sample well overlayed on the isotype control. 




As the demarcation between the positive and negative expression was uncertain in 
some of the samples, it was necessary to manually visualise the population and 
make a decision based on the dot plot. This was done by placing the channel of 
interest on the X-axis and on the Y-axis switching between FSC, SSC and the other 
two channels (FL1, FL2 or FL4) and placing quadrants to separate the populations. 
Once the correct percentage of positive expression was determined, the histogram 
was adjusted to accommodate the change and the statistics were updated. In some 
instances it was not clear what the decision should be in which case the marker was 
flagged and would be decided upon after further investigation at a later stage.  Once 
this was completed for all wells in all channels, the statistics were exported to a 
Microsoft Excel spread sheet in preparation for statistical analysis. 
 
2.7. Statistical analysis of flow cytometry data 
 
Statistical analysis of the data included performing repeated measures ANOVA, 
paired t-tests and independent two-sample t-tests using R statistical software 
(Vienna, Austria). 
 
2.7.1. Repeated measures ANOVA 
 
This statistical analysis is used when there is a variable being measured two or more 
times in an experiment on the same experimental group. In the case of this study, 
the variable was each of the 252 markers, which were measured at three different 
time points in the same group of 33 people. 
The repeated measures ANOVA is used to test whether there are any differences 










2.7.2. Paired t-test 
 
A paired t-test was used to determine if there was a significant difference between 
the values of two means of a related sample under the same conditions. In this case 
it was used to determine if there was a significant difference between time points e.g.  
 Baseline (Dx) vs Week 4 (W4) 
 Baseline (Dx) vs Week 24 (W24) 
 Week 4 (W4) vs Week 24 (W24) 
 
The null hypothesis is:       where the means are equal from any paired group. 
The paired t test is a more powerful test than the unpaired t test but only when there 
are matched samples.  
 
2.7.3. Independent two-sample t-test 
 
The three groups of samples in this study, TB patients, healthy community controls 
and other lung disease (OLD) controls, are not of equal size, which allows us to use 
the independent two-sample t-test, also known as the unequal variance t-test. In this 
case the Welch Approximate Degrees of Freedom (APDF) test was used with the 
hypothesis that there are equal means from two independent groups (55).   This test 
will allow us to detect if the means between any two groups are different e.g. 
 TB patients at baseline vs healthy community controls 
 TB patients at baseline vs other lung disease controls 











2.7.4. Bonferroni correction 
 
Due to the fact that the probability of finding at least one significant result by chance 
increases with the number of markers that are tested, it was necessary to apply the 
Bonferroni correction to the statistical analysis. This is a very stringent and 
conservative form of statistical analysis as it took 252 markers into consideration.  
Thus the Bonferroni correction was applied to limit the chances of obtaining false 
positive results when using a single set of data (56). Using this Bonferroni correction, 
if we let the test       , then we should only consider the markers with p-value 
 
    
   
       . 
 
2.7.5. Ingenuity pathway analysis (IPA) and Qlucore heat maps  
 
Ingenuity pathway analysis (IPA®,Qiagen Redwood City, www.qiagen.com/ingenuity) 
was performed on a selection of markers with the goal of identifying all potential 
biological pathways that changed during treatment as the relatively small study size 
of 33 patients and the strict Bonferroni correction may lead to false negative results. 
Surface markers that had a p-value <0.01 before the Bonferroni correction was 
applied were considered for IPA.  Due to the uncertainty of demarcation between the 
negative and positive populations, markers that were flagged were excluded from 
IPA and heat map generation.  The accession number for each marker was obtained 
from the UniProt (http://www.uniprot.org/) website (Table 3.7).  Data input into the 
IPA software included a parameter for up- or down-regulation between time points 
and the resulting pathways were organised according to the number of molecules 
(surface markers) involved in the pathway as well as their p-values. 
Based on the results from the repeated measures ANOVA, paired t-test and 
independent t-test, the markers were categorised and analysed as follows (Table 
3.13): 
 Repeated measures ANOVA (overall treatment response) - 17 markers  
 Paired t-test TB diagnosis vs week 24 – 18 markers 
 Paired t-test TB diagnosis vs week 4 – Five markers 
 Paired t-test Week 4 vs week 24 – Eight markers 




 Independent t-test TB diagnosis vs healthy community controls – 14 markers 
 Independent t-test TB diagnosis vs OLD – 12 markers 
 
Markers that were excluded from IPA analysis included flagged wells and in the case 
of duplicate wells, only one of the duplicates was included. In the case of CD45RB, 
CD45RO and CD15, an accession number for humans could not be sourced through 
the UniProt database thus were excluded.  HLA included a cocktail of HLA-A, HLA-B 
and HLA-C which prevented the use of a single accession number. Since it could not 
be determined from this study which HLA was influencing the overall expression, it 
was decided to exclude it. Similarly MIC A/B was a combination of MIC A and MIC B 
and was excluded on the same rationale as HLA. 
 
Heat maps were generated using the Qlucore Omics Explorer software (Lund, 
Sweden) on selected markers identified when comparing the change in expression 
between TB diagnosis and week 24 using repeated measures ANOVA analysis 
(Table 3.8).  As for the IPA analysis, this was a proof-of-concept approach and we 
decided not to limit the analysis to the few markers that remained significantly 
different after the correction.  All heat maps were obtained in an unbiased manner 
and were generated to create the following comparisons: 
 
 TB patients at diagnosis, week 4 and week 24 (Figure 3.8) – 18 markers were 
used and showed a significant difference, especially between diagnosis and 
week 24. It appears that changes in the expression levels started changing from 
as early as week 4 however these changes were not statistically significant once 
the Bonferroni correction was applied. 
 TB patients at diagnosis, week 24 and healthy community controls (Figure 3.11). 








2.7.6. Association between expression of markers at diagnosis and study 
outcomes 
 
Statistics were performed to determine the association between the expression of 
markers at diagnosis of disease and the following variables: 
 Treatment outcome (definite cure, probable cure and not cured): Only 
comparisons between definite cure and not cured were performed as the clinical 
relevance of identifying a probably cure group are not yet clearly understood. 
 Time to positivity (TTP): A simple correlation between marker expression at 
baseline and TTP was performed. 
 Week 8 culture result: A comparison between the surface marker expression and 
the week 8 culture result was performed. 
 Qualitative scan outcome: An association between the marker expression at 
diagnosis and the PET/CT outcome at EOT (Resolved, mixed and improved) was 
performed. A mixed response indicates that at least some lesions enlarge or show 
more intense uptake at EOT compared to diagnosis or that at least one new lesion 
has developed. An improved response indicates that all lesions with abnormal 
uptake have improved from diagnosis but that at least one lesion has abnormal 
isotope uptake. Resolved indicates that no lesions remain with increased uptake. 
 New clinical groups by combination of the qualitative and quantitative scan 
outcomes: New outcome groups were formed by combining the original qualitative 
and quantitative groups to classify patients in clinical severity groups (table 2.7).  
Quantitative groups are indicated by the percentage of lung volume abnormal at 
EOT (Week 24), on both PET and CT.  0-1% = 1 (Best scan outcome); 1-2% = 2; 
2-4% = 3; 4-6% = 4; >6% = 5 (worst outcome). 
 
Table 2.7  Table of the new scan outcome groups 
New group Original group (Quantified scale 1-5) 
Good Resolved 
 Improved with a quantitative score of 1 
Moderate Improved with a quantitative score of 2 
 Mixed with a quantitative score of 1 
Poor Improved with a quantitative score of 3 or more 
 Mixed with a quantitative score of 2 or more 
 




Chapter 3: Results 
 
3.1. Objective 1 - Optimisation of FACSTM CAP procedures.  
 
3.1.1. Objective 1.1: Assess the effect of cryopreservation on FACSTM CAP 
performance.   
 
Five healthy volunteers were recruited to determine the effect of cryopreservation on 
the expression of surface markers on PBMC’s. The statistical analysis was 
performed according to the following criteria:    
 Only surface markers that showed a difference in expression of 5% or more were 
chosen. 
 Only surface markers that showed a difference in four or more patients were 
considered. 
 Markers that were flagged, due to indeterminate analysis, were excluded from 
statistical analysis as well as the markers that exhibited a decrease in some 
patients and an increase in others. 
Results of the comparison of surface markers between fresh and cryopreserved 
samples showed only five markers (Table 3.1) with a notable difference.  Four 
markers (CD41a, CCR6, CD9 and CD62L) showed a down-regulation between fresh 
and frozen and one marker (CD7) showed an up-regulation. The outcome of this 
experiment showed that besides the five markers listed above; there was no notable 
difference when comparing the expression of surface markers between fresh and 
cryopreserved PBMCs.  It was decided early in the project to continue with freshly 








Table 3.1: Surface markers with up- or down-regulation when comparing fresh and 
cryopreserved PBMCs 
  Patient HC01 Patient HC02 Patient HC04 Patient HC05 Patient HC06   
Marker 
Fresh Frozen Fresh Frozen Fresh Frozen Fresh Frozen Fresh Frozen P-value 
CD41a 11.9 3.75 15.6 4.19 21.3 5.81 27.7 9.4 8.91 7.44 0.0202 
CCR6 18.3 10.4 13.6 6.02 23.2 13.1 13 3.49 26.2 24.2 0.0067 
CD9 27.3 19.4 33.1 23.6 34.7 27.6 37.3 19 18.4 20.7 0.069 
CD62L 53.9 37.5 61.9 46.8 78.4 47.3 33.3 14 17.9 13.2 0.015 




3.1.2. Objective 1.2: Assess the effect of PBMC culture in the presence of Mtb 
antigen stimulation on marker expression in comparison to 
unstimulated PBMCs. 
 
Five TB patients were recruited to determine the change in surface marker 
expression levels after stimulation of PBMC’s with PPD. The statistical analysis was 
performed as outlined for the comparison of fresh and cryopreserved cells above 
(section 3.1.1). 
The expression of surface markers was highly variable between patients.  Markers 
such as CD41a, CD45Ra and CD61 were down-regulated when comparing 
stimulated with unstimulated PBMC’s and expression for markers such as CD4v4, 
CD49a and CD62L were up-regulated in stimulated compared with unstimulated 








Table 3.2: Surface markers with up- or down-regulation when comparing unstimulated and 
PPD stimulated cells. 
  Patient S191 Patient S192 Patient S193 Patient S201 Patient S203   
Marker Stim Unstim Stim Unstim Stim Unstim Stim Unstim Stim Unstim P-value 
CD41a 5.04 30.9 11.6 37.1 2.09 15.3 7.64 24.3 12.9 12.1 0.0302 
CD45RA 64.9 74.9 58.2 57 0.71 57.8 34.3 39.8 72.9 87.9 0.1689 
CD61 7.14 14.5 8.34 29.8 3.52 13 2.47 12.8 12.1 11.5 0.0532 
CD4 v4 37 28.5 44.2 25.3 42.5 37.1 62.5 55.7 9.82 7.37 0.04 
CD49a 32.1 16.1 3.95 2.49 9.58 1.9 15.7 5.13 9.38 4.34 0.03 
CD62L 59.2 37.6 60.3 39 36 31.4 77.4 60.5 24.9 19.5 0.0205 
 
  
It was noted that there was no significant change in the expression of activation 
markers when comparing unstimulated and PPD stimulated PBMC’s (Table 3.3).  
The gating strategy for the analysis of these samples included the entire population 
of PBMCs where the PPD responsive T cells represent a small percentage.  As only 
six markers showed a consistent change in expression between unstimulated and 
stimulated samples, it was decided to continue with the project using unstimulated 
PBMCs. 
 
Table 3.3: List of common activation markers displaying no significant changes between PPD 
stimulated and unstimulated PBMCs 
  Patient S191 Patient S192 Patient S193 Patient S201 Patient S203   




DR 48.5 35.5 24.9 38.3 50.3 43.1 21.2 18.3 93.3 80.6 0.4076 
CD69 0.25 2.01 7.91 9.97 2.35 0.84 1.42 0.89 1.01 21 0.334 
CD25 1.14 1.51 2.61 9.26 0.34 1.03 1.91 7.59 1.96 1.86 0.1398 
CD71 1.77 3.79 4.57 5.68 2.75 1.8 2.43 3.36 7.39 11.1 0.147 
CD62L 37.6 59.2 39 60.3 31.4 36 60.5 77.4 19.5 24.9 0.0205 
 
  




3.2. Objective 2: To assess the differential PBMC surface marker expression 
by FACSTM CAP in TB patients during treatment. 
 
All patients recruited into the study were analysed however, only 33 patients, for 
which there were three time points, were considered for the final statistical analysis.  
Nine other lung disease (OLD) and 11 healthy community controls were also 
included in the statistical analysis.  The initial study design included an algorithm that 
could be used for automated analysis however due to the high variability of the data 
it would not have been accurate enough to use. Therefore all patient data was 
analysed manually using the FlowJo software by gating on the lymphocyte 
population.  The isotype controls provided  a cut-off between a positive and negative 
expression result although adjustments were made if necessary by relying on the 
profile of the expression in a dot plot using parameters two by two  ( FSC, SSC, FL1, 
FL2, FL4).  In a case where the expression of a marker was unclear, the well was 
flagged and left to be decided after all patients were analysed and comparisons 
could be made. Wells that were still unclear were represented as flagged in the 
results tables and not included in further analysis.  
 
3.2.1. Significant markers identified for overall treatment response (between 
diagnosis, week 4 and week 24). 
 
Repeated measures ANOVA was performed on 252 markers and resulted in five 
markers with expression levels that were statistically significant between the time 
points (< 0.0002 after the Bonferroni correction was applied). The markers were 
CD120b, CD126, CD62L, CD48 and CD29.  The expression levels of CD120b, 
CD126 and CD62L were significantly decreased during the course of treatment while 
CD48 and CD29 were both increased between diagnosis and end of treatment.    
 
Of the 252 markers that were used, 29 had a p-value of <0.01 after the Bonferroni 
correction was applied (Table 3.4).  A p-value of 0.01 was a random choice and 
allowed the investigation of a large number of markers with significant change or 
trends.  Of the 29 markers, 24 were not significantly different; however, due to the 
small sample number and the application of the stringent Bonferroni correction, 




these markers may have been falsely negative and may still be of biological 
significance.    A total of 11 markers were identified as flagged and while they were 
included in the initial results, they were excluded from further analysis due to their 
ability to erroneously skew results.  Kernel density graphs for selected markers 
demonstrate the distribution of expression when comparing the expression levels of 
surface markers between TB diagnosis and at the end of treatment. 
 
Table 3.4: Selected markers from the repeated measures ANOVA analysis (p-values from 
repeated measures ANOVA test <0.01 before the Bonferroni correction). 




T0 W4 W24 Healthy Other 
      (N=33) (N=33) (N=33) (N=11) (N=9) 
CD50 97.72 98.36 98.92 99.35 99.1 0.0005 0.1270 NO 
CD48 96.88 97.6 98.75 99.37 98.18 0.0001 0.0298 NO 
CD99 75.84 82.68 88.05 91.2 70.1 0.0011 0.2674 YES 
CD58 61.63 68.23 70.5 75.51 56.14 0.0035 0.8865 NO 
CD91 2.8 3.54 4.69 3.66 2.16 0.0077 1.9513 NO 
CD4 v4 31.44 27.9 23.59 26.09 32.36 0.0055 1.3770 NO 
CD244 35.27 38.75 49.06 48.62 28.16 0.0011 0.2790 YES 
CD146 2.9 3.24 2.12 1.64 1.95 0.0051 1.2768 NO 
CD120b 14.96 8.91 5.39 14.96 6.21 0.0000 0.0035 NO 
NKG2D 45.4 50.89 52.99 51.26 39.01 0.0048 1.1999 YES 
CD53 98.03 98.39 98.97 98.94 98.74 0.0018 0.4642 NO 
CD45RB 97.34 98.05 98.62 99.05 98.53 0.0021 0.5251 NO 
CD126 80.58 79.7 63.26 50.15 67.89 0.0000 0.0000 NO 
F11 R 97.19 95.98 95.29 95.89 94.28 0.0017 0.4280 NO 
CD210 22.48 28.88 40.69 53.38 24.45 0.0089 2.2381 YES 
CD119 13.83 11.81 26.28 21.61 10.15 0.0005 0.1370 YES 
CD29 89.88 91.79 95.25 95.96 94.09 0.0008 0.2054 NO 
CD29 91.85 92.03 95.04 94.99 93.52 0.0001 0.0166 NO 
CD29 91.09 92.63 95.26 96.24 95.28 0.0025 0.6389 NO 
CD44 98.42 99.09 99.16 99.35 98.89 0.0083 2.0945 NO 
CD11a 97.54 98.58 99 99.55 98.13 0.0006 0.1523 NO 
CD212 6.86 4.23 18.82 29.01 17.98 0.0003 0.0677 YES 
CD55 67.28 56.67 47.3 46.69 82.24 0.0004 0.0987 YES 
CD4 35.56 30.85 27.05 30.71 37.7 0.0040 0.9985 NO 
CD181 19.59 16.48 25.19 25.11 11.31 0.0005 0.1164 YES 
CD81 98.18 98.3 99.16 99.3 99.38 0.0012 0.3013 NO 
CD4 35 30.89 27.38 28.63 37.37 0.0074 1.8610 NO 
CD62L 45.82 35.39 25.37 30.6 42.66 0.0000 0.0035 NO 
CCR7 31.24 24.03 21.98 20.62 37.96 0.0053 1.3465 NO 






















Distribution of expression of CD126 (a), CD120b (b), CD62L (c) and CD48 (d).  PBMCs were isolated, 
stained and acquired on a flow cytometer to evaluate the expression of markers on the cells surface.  
The expression is denoted as a percentage of the total cells expressing the marker.  The comparison 
was made between the expression levels at TB diagnosis, week 4 and week 24.  A change in 
expression was considered significant if the p-value <0.0002 after the application of the Bonferroni 
correction.  
B. CD120b: TB (Dx), W4 and W24 A. CD126: TB (Dx), W4 and W24 
C.  CD62L: TB (Dx), W4 and W24 D.  CD48: TB (Dx), W4 and W24 
Figure 3.1: Kernel density graphs comparing the distribution of expression of markers 
between TB diagnosis, week 4 and week 24.  
 






















Distribution of expression of CD29 (a), CD4 (b), CD11a (c) and F11 R (d).  PBMCs were isolated, 
stained and acquired on a flow cytometer to evaluate the expression of markers on the cells surface.  
The expression is denoted as a percentage of the total cells expressing the marker.  The comparison 
was made between the expression levels at TB diagnosis, week 4 and week 24.  A change in 
expression was considered significant if the p-value <0.0002 after the application of the Bonferroni 
correction.  
B.   CD4: TB (Dx), W4 and W24 A. CD29: TB (Dx), W4 and W24 
C.   CD11a: TB (Dx), W4 and W24 D.   F11 R: TB (Dx), W4 and W24 
Figure 3.2: Kernel density graphs comparing the distribution of expression of markers between 
TB diagnosis, week 4 and week 24. 

















Distribution of expression of CCR7 (a) and CD58 (b).  PBMCs were isolated, stained and acquired on 
a flow cytometer to evaluate the expression of markers on the cells surface.  The expression is 
denoted as a percentage of the total cells expressing the marker.  The comparison was made 
between the expression levels at TB diagnosis, week 4 and week 24.  A change in expression was 




Coincidentally anti-CD4 and anti-CD126 were in the same well which allowed us to 
investigate the co-expression of CD4 and CD126 on cells at all three time points.  
CD126 was expressed on both CD4+ and CD4- cells however, the significant down-
regulation of CD126 occurred primarily on the CD4- population (p-value of 0.0001 
before the Bonferroni correction). 
B.   CD58: TB (Dx), W4 and W24 A.  CCR7: TB (Dx), W4 and W24 
Figure 3.3: Kernel density graphs comparing the distribution of expression of markers between 
TB diagnosis, week 4 and week 24. 























The addition of both CD4 and CD126 in the same well allows the illustration of the co-expression of 
CD4 and CD126.  It is evident that the significant down-regulation of CD126 occurs on CD4- cells. 
























































































































































































































































































C.    Week 24 
Figure 3.4:  The co-expression of CD4 and CD126 in a TB patient (S147 Dx), at three time points. 




CD4 (Table 3.4) shows a high expression level before treatment in TB patients but 
then decreases after the start of treatment to eventually reach post-treatment levels 
comparable to those in healthy community controls. Similarly, CD8 and CD57 
increase in expression after the start of treatment. Although these markers are not 
significantly different after the application of the Bonferroni correction, they may be 
significant biologically and deserve to be followed up with another study.  Other 
markers of interest such as CCR7, CD127, CD27 and HLA-DR all show a trend of 
increased or decreased expression however this was not significant after the 
Bonferroni correction. 
 
3.2.1.1. IPA pathways associated with significant markers in overall treatment 
response (between diagnosis, week 4 and week 24). 
 
IPA was performed on 17 markers that had a p-value <0.01 before the Bonferroni 
correction was applied. Twenty three pathways had associations with at least two 
markers (Table 3.5).  The top nine will be discussed.  The first three pathways are 
illustrated in figures 3.5 – 3.7. 
 
Table 3.5: Table of pathways associated with overall treatment response (between diagnosis 
and week 24) 
 
 
Pathway Number of markers 
involved 
Leukocyte extravasation signalling 5 
Crosstalk between Dendritic cells and Natural killer cells 4 
Granulocyte adhesion and diapedesis 4 
Caveolar-mediated endocytosis signalling 3 
NF-κβ activation by viruses 3 
Dendritic cell maturation 3 
Hepatic fibrosis/Hepatic stellate cell activation 3 
Role of osteoblasts, osteoclasts and chondrocytes in 
Rheumatoid Arthritis 
3 
T Helper cell differentiation 2 



















Leukocyte extravasation pathway illustrating the involvement of CD44, CD50, CD29, CD11a and F11-R. Markers highlighted as red were up-regulated at 
week 24. 
Leukocyte extravasation signalling 
Figure 3.5: The leukocyte extravasation signalling pathway  
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The crosstalk between Dendritic cells and Natural killer cells pathway illustrating the involvement of CD120b, CCR7, CD11a and CD50. The markers 
highlighted in red indicate an up-regulation at week 24 and the markers in grey are down-regulated at week 24 
Crosstalk between Dendritic cells and Natural killer cells 
Figure 3.6: The crosstalk between Dendritic cells and Natural killer cells pathway  
 
Stellenbosch University  https://scholar.sun.ac.za


























The granulocyte adhesion and diapedesis pathway illustrating the involvement of 4 markers. The 
markers highlighted in red indicate an up-regulation at week 24 and the markers in grey are down-
regulated at week 24. 
Granulocyte adhesion and diapedesis 
Figure 3.7: The granulocyte adhesion and diapedesis pathway 




3.2.2. Significant markers identified when comparing surface marker 
expression between two time points. 
 
The paired t-test was applied to determine which markers would show a significant 
difference between two time points. The time points were compared as follows: 
 
 Baseline (Dx) vs Week 4 (W4) 
 Baseline (Dx) vs Week 24 (W24) 
 Week 4 (W4) vs Week 24 (W24) 
 
After the Bonferroni correction was applied, 41 markers showed a possible trend of 
change (p-value <0.01) (highlighted in blue in table 3.6). A comparison of marker 
expression between Dx and W4 did not yield any markers that were statistically 
different however, there were five markers that had a p-value <0.01 (Table 3.6).  The 
comparison of expression between Dx and W24 resulted in five markers that were 
statistically different (CD120b, CD126, CD62L, CD29 and CD48) as well as 28 
markers that had a p-value <0.01 (Table 3.6). Finally the comparison between W4 
and W24 resulted in two markers whose expression was statistically different 
(CD120b and CD29) and 11 markers with a p-value <0.01 (Table 3.6). Thirteen 














Table 3.6: Selected markers from paired t-test analysis (p-values from paired t-test <0.01) 
 
 
Diagnosis vs week 4 Diagnosis vs 
week 24 
Week 4 vs week 24 Flagged 
  P-value P-val*252 P-value P-val*252 P-value P-val*252   
CD50 0.0140  3.5247  0.0015  0.3707  0.0462  11.6322  NO 
CD48 0.0989  24.9149  0.0000  0.0030  0.0152  3.8403  NO 
CD99 0.0458  11.5395  0.0010  0.2557  0.0538  13.5601  YES 
CD58 0.0199  5.0110  0.0015  0.3782  0.3912  98.5902  NO 
CD95 0.0976  24.6037  0.0010  0.2595  0.3213  80.9563  YES 
CD91 0.1435  36.1675  0.0043  1.0818  0.0837  21.0827  NO 
CD45RO 0.7374  185.8259  0.0295  7.4297  0.0045  1.1450  NO 
CD4 v4 0.1510  38.0616  0.0007  0.1689  0.0945  23.8050  NO 
CD85 0.8028  202.2980  0.0022  0.5566  0.0379  9.5403  YES 
CD244 0.3593  90.5329  0.0003  0.0649  0.0132  3.3157  YES 
CD15 0.5238  131.9869  0.0065  1.6495  0.0925  23.3068  NO 
CD49c 0.0670  16.8798  0.0097  2.4484  0.3710  93.4987  YES 
CD18 0.2153  54.2550  0.0011  0.2833  0.1019  25.6879  NO 
CD146 0.3195  80.5190  0.0389  9.8070  0.0014  0.3442  NO 
CD120b 0.0021  0.5268  0.0000  0.0079  0.0626  15.7659  NO 
CD107a 0.0175  4.4043  0.0064  1.6169  0.4402  110.9292  NO 
CD66 0.3107  78.3034  0.0038  0.9645  0.0854  21.5320  YES 
NKG2D 0.0228  5.7406  0.0047  1.1859  0.3210  80.9033  YES 
CD53 0.2058  51.8651  0.0008  0.2099  0.0154  3.8882  NO 
CD45RB 0.0948  23.8970  0.0031  0.7818  0.0029  0.7318  NO 
CD126 0.7083  178.4965  0.0000  0.0000  0.0000  0.0001  NO 
F11 R 0.0004  0.0935  0.0020  0.5001  0.2701  68.0658  NO 
CCR6 0.0911  22.9674  0.4048  101.9992  0.0085  2.1298  NO 
CD210 0.1647  41.4951  0.0035  0.8699  0.0949  23.9250  YES 
CD119 0.1478  37.2562  0.0111  2.7916  0.0030  0.7591  YES 
CD29 0.2080  52.4121  0.0040  1.0102  0.0000  0.0005  NO 
CD29 0.8300  209.1541  0.0005  0.1267  0.0000  0.0026  NO 
CD29 0.2613  65.8401  0.0042  1.0507  0.0003  0.0755  NO 
CD11a 0.0092  2.3179  0.0048  1.2046  0.0292  7.3567  NO 
CD62P 0.8098  204.0718  0.0346  8.7124  0.0092  2.3105  NO 
CD212 0.2105  53.0471  0.0082  2.0636  0.0011  0.2708  YES 
CD55 0.0524  13.2061  0.0001  0.0329  0.0373  9.4036  YES 
CD4 0.0650  16.3846  0.0014  0.3561  0.1324  33.3695  NO 
CD181 0.1705  42.9602  0.0244  6.1414  0.0000  0.0038  YES 
CD81 0.6803  171.4344  0.0007  0.1737  0.0030  0.7631  NO 
CCR4 0.0044  1.0972  0.1311  33.0382  0.5449  137.3023  NO 
CD4 0.0865  21.7936  0.0014  0.3414  0.1729  43.5593  NO 
CD28 0.2122  53.4683  0.0059  1.4795  0.1934  48.7462  NO 
CD62L 0.0081  2.0321  0.0000  0.0008  0.0324  8.1542  NO 
CCR7 0.0134  3.3803  0.0014  0.3407  0.5311  133.8273  NO 










3.2.2.1. IPA pathways associated with significant markers when comparing 
surface marker expression between two time points.  
 
3.2.2.1.1. Comparison of marker expression between TB diagnosis and week 4 
 
Five markers were analysed and resulted in four pathways with an association of two 
or more markers under investigation. The first ten pathways, associated with one or 
more surface markers, are listed in table 3.7. 
 
3.2.2.1.2. Comparison of marker expression between TB diagnosis and week 24  
 
Eighteen markers resulted in 33 pathways with an association of two or more 
markers under investigation. The first ten pathways, associated with one or more 
surface markers, are listed in table 3.7. 
 
3.2.2.1.3. Comparison of marker expression between week 4 and week 24   
 
Eight markers resulted in two pathways with an association of two or more markers 
under investigation. The first ten pathways, associated with one or more surface 


























 TB Dx vs W4 TB Dx vs W24 W4 vs W24 TB Dx vs healthy TB Dx vs OLD 
1 Granulocyte adhesion 
and diapedesis 
Crosstalk between DC 





Crosstalk between DC 
and NK cells 
2 Crosstalk between DC 








3 Tight junction signalling Caveolar mediated 
endocytosis signalling 
Role of JAK family 
kinases in IL-6 type 
cytokine signalling 
Agrin interaction and 
neuromuscular 
junctions 
NF-κβ activation by 
viruses 
4 Leukocyte extravasation 
signalling 




NF- κβ  activation by 
viruses 
Coagulation system 
5 Tumoricidal function of 
hepatic NK cells 
Leukocyte extravasation 
signalling 
Regulation of cellular 
mechanics by Calpain 
protease 
Reelin signalling in 
neurons 
Role of macrophages, 
fibroblasts and 
endothelial cells in 
Rheumatoid arthritis 
6 TNFR2 signalling T helper cell 
differentiation 
Actin nucleation by 
ARP-WASP Complex 




7 Induction of apoptosis 
by HIV-1 
Agrin interaction and 
neuromuscular 
junctions 
T helper cell 
differentiation 
Paxilin signalling PPAR signalling 
8 T helper cell 
differentiation 
Reelin signalling in 
neurons 
Agrin interaction and 
neuromuscular 
junctions 
PTEN signalling Role of tissue factor in 
cancer 




between innate and 





Type II diabetes mellitus 
signalling 
10 Caveolar mediated 
endocytosis signalling 
Virus entry via 
endocytic pathways 
TREM1 signalling Integrin signalling PTEN signalling 
Stellenbosch University  https://scholar.sun.ac.za




3.2.2.2. Heat map illustrating the change in expression between TB diagnosis, 
week 4 and week 24. 
 
A comparison of 18 markers (Table 3.8) between TB patients at diagnosis, week 4 
and week 24 showed a change of the expression levels of most of the markers 
especially between diagnosis and week 24. It appears that changes in the 
expression levels started changing from as early as week 4 however these changes 















Heat map generated to compare the expression levels of markers between TB diagnosis, week 4 and 

















Figure 3.8: Heat map comparing expression of TB diagnosis, week 4 and week 24. 




Table 3.8: List of surface markers used to generate Qlucore heat maps 
Surface markers 
CD classification Alternative name CD classification Alternative name 
CD50 ICAM-3 CD126 IL-6R 
CD48 BLAST-1 F11 R JAM1 
CD58 LFA-3 CD44 HCAM 
CD91 LRP1 CD11a ITGAL 
CD4 v4 Clone L120 CD4 CD4 
CD146 MCAM CD81 TAPA-1 
CD120b TNFR2 CD62L L-selectin 
CD53 Tetraspanin-25 CCR7 CD127 
CD45RB CD45 CD29 ITGB1 
 
Based on the results of the heat maps, it was decided to perform IPA on smaller 
groups of markers that showed a similar trend (up-regulation or down-regulation) to 
identify pathways associated with the markers that behaved in the same manner 
during treatment (Tables 3.8 and 3.9).   The top five pathways for each group had an 
association with two or more markers (Table 3.11). 
 
Table 3.9: Markers up-regulated between diagnosis and week 24 







Table 3.10: Markers up-regulated between diagnosis and week 24 
Markers down-regulated between diagnosis 
and week 24 
CD126 CCR7 
CD146 CD62L 
F11 R CD4 
CD120b CD4 v4 





Table 3.11: List of the top five Ingenuity pathways associated with the markers which showed 
an up-regulation (left) and down-regulation (right) when used to generate a heat map using the 
Qlucore Omics Explorer software.    
 
 
3.2.3. Significant markers identified when comparing surface marker 
expression between two different patient groups. 
 
When comparing the mean expression between TB patients (at diagnosis) with 
healthy community controls and other lung disease controls, it was assumed that the 
mean of all the groups was equal.  A comparison between TB patients and healthy 
community controls using the independent two-sample t-test resulted in 23 markers 
with a p-value  < 0.01; however, only four proved to be statistically different (CD48, 
CD18, CD126 and fMLPr).   Similarly, a comparison between TB patients and OLD 
controls and between healthy controls and OLD controls resulted in 13 and 9 
markers respectively (highlighted in blue in table 3.12), with a p-value <0.01; 
however, after the Bonferroni correction was applied, only one marker was 
significant for the comparison of TB patients and OLD controls (CD220). CD220 had 
a negative expression level (<10% expression) and therefore was not considered 
biologically significant. CD126 was found to be significantly different and able to 
distinguish between TB patients before treatment (Dx) and healthy controls. CD48 
and CD18 were both significantly different between TB diagnosis and healthy 
Up-regulation between Dx and W24 Down-regulation  between Dx and W24 
Leukocyte extravasation signalling Hepatic fibrosis/Hepatic stellate cell activation 
Caveolar-mediated endocytosis signalling T Helper cell differentiation 
Agrin interactions at neuromuscular 
junctions 
Communication between innate and adaptive 
immune cells 
NF-κβ activation by viruses Crosstalk between dendritic cells and natural 
killer cells 
Reelin signalling in neurons IL-6 signalling 




controls; however, as the expression levels of these markers were both 
predominantly positive, the result was not biologically significant. It was noted that 
there is a more noticeable difference between TB patients before treatment and 
healthy controls than between TB patients and OLD controls and between OLD 
controls and healthy controls.  Kernel density graphs for selected markers 
demonstrate the distribution of expression when comparing the expression levels of 
surface markers between TB patients at diagnosis, healthy community controls and 
OLD controls. 




Table 3.12: Selected markers from the independent two-sample t-test analysis (p-values from independent two-sample t-test <0.01) 
Marker Means 
TB diagnosis vs 
healthy control 
TB diagnosis vs OLD Healthy control vs OLD Flagged 
  T0  Healthy Other  P-value P-val*252 P-value P-val*252 P-value P-val*252   
  (N=33)   (N=11) (N=9)               
CD6 63.19 75.83 60.07 0.0085  2.1364  0.5883  148.2557  0.0207  5.2261  YES 
CD50 97.72 99.35 99.1 0.0015  0.3699  0.0014  0.3582  0.5342  134.6176  NO 
CD48 96.88 99.37 98.18 0.0000  0.0020  0.0806  20.3086  0.0619  15.6102  NO 
CD99 75.84 91.2 70.1 0.0074  1.8661  0.5774  145.4938  0.0606  15.2712  YES 
CD147 98.05 99.27 98.62 0.0016  0.4057  0.2273  57.2877  0.1498  37.7410  NO 
CD95 51.19 63.41 43.99 0.0344  8.6788  0.2422  61.0361  0.0100  2.5094  YES 
CD64 2.12 2.03 1.11 0.8797  221.6964  0.0025  0.6322  0.1337  33.6808  NO 
CD45 99.17 99.94 99.68 0.0022  0.5490  0.0523  13.1806  0.0508  12.7960  NO 
CD66b 1.62 0.85 1.91 0.0040  1.0083  0.6935  174.7673  0.1724  43.4437  NO 
CLA 8.12 8.15 5.43 0.9851  248.2381  0.0014  0.3554  0.0263  6.6380  NO 
CD18 98.43 99.69 99.1 0.0001  0.0237  0.0414  10.4236  0.0150  3.7689  NO 
HLA 99.44 99.95 99.74 0.0053  1.3377  0.1353  34.0876  0.0981  24.7268  NO 
CD146 2.9 1.64 1.95 0.0011  0.2697  0.0330  8.3105  0.4290  108.1051  NO 
CD120b 14.96 14.96 6.21 0.9994  251.8503  0.0028  0.7160  0.1115  28.0903  YES 
CD107a 4.23 3.78 2.53 0.5763  145.2204  0.0030  0.7486  0.1527  38.4774  NO 
CD109 56.6 29.96 46.04 0.0013  0.3356  0.1980  49.8940  0.0975  24.5774  YES 
TGFBR2 6.73 2.77 3.54 0.0016  0.3931  0.0148  3.7415  0.3250  81.9115  NO 
Ly b R 3 2.23 1.69 0.0931  23.4728  0.0040  1.0082  0.2671  67.3090  NO 
MIC AB 6.55 2.77 5.49 0.0020  0.4941  0.5524  139.1988  0.1404  35.3703  NO 
CD140a 1.74 1.1 1.23 0.0035  0.8741  0.0287  7.2410  0.5348  134.7670  NO 
CD130 30.62 20.49 40.7 0.0274  6.9004  0.1417  35.7175  0.0090  2.2643  YES 
CD150 33.57 38.92 24.02 0.2370  59.7252  0.0346  8.7309  0.0053  1.3341  YES 
CD45RB 97.34 99.05 98.53 0.0013  0.3308  0.0268  6.7645  0.2854  71.9209  NO 
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CD126 80.58 50.15 67.89 0.0000  0.0001  0.0118  2.9816  0.0029  0.7331  NO 
CD16b 17.42 10.64 24.76 0.0110  2.7779  0.0523  13.1849  0.0007  0.1841  YES 
CD141 2.22 1.36 1.22 0.0308  7.7700  0.0054  1.3610  0.6706  168.9887  NO 
CD210 22.48 53.38 24.45 0.0064  1.6199  0.8096  204.0294  0.0217  5.4793  YES 
CD220 1.34 1.29 0.68 0.8433  212.4995  0.0001  0.0303  0.0366  9.2171  NO 
Le B4 R 3.53 2.23 2.32 0.0083  2.1008  0.0236  5.9396  0.8683  218.8242  NO 
CD87 0.89 0.95 0.35 0.8944  225.3813  0.0017  0.4233  0.1792  45.1546  NO 
fMLP r 17.43 7.23 10.84 0.0000  0.0071  0.0481  12.1132  0.1965  49.5056  YES 
CD29 89.88 95.96 94.09 0.0032  0.8040  0.0234  5.9029  0.1881  47.4022  YES 
CD29 91.09 96.24 95.28 0.0011  0.2791  0.0052  1.3176  0.3758  94.6920  YES 
CD11a 97.54 99.55 98.13 0.0026  0.6471  0.6694  168.6998  0.2761  69.5675  NO 
CD33 3.22 2.85 1.65 0.5451  137.3778  0.0014  0.3476  0.0319  8.0447  NO 
CD55 67.28 46.69 82.24 0.0121  3.0421  0.0944  23.7903  0.0019  0.4864  YES 
CD81 98.18 99.3 99.38 0.0136  3.4158  0.0007  0.1831  0.8399  211.6501  NO 
CD20 13.56 19.12 18.21 0.0038  0.9567  0.1620  40.8345  0.7817  196.9960  NO 
CCR9 23.3 10.46 7.55 0.0311  7.8410  0.0034  0.8485  0.5340  134.5687  YES 
CD8 23.04 36.12 17.56 0.0201  5.0683  0.0418  10.5418  0.0024  0.6127  NO 
CD235a 0.99 0.6 1.46 0.0425  10.6989  0.0752  18.9388  0.0012  0.3050  NO 
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Distribution of expression of CD126 (a), CD120b (b), CD8 (c) and CD11a (d).  PBMCs were isolated, 
stained and acquired on a flow cytometer to evaluate the expression of markers on the cells surface.  
The expression is denoted as a percentage of the total cells expressing the marker.  The comparison 
was made between the expression levels of TB patients at diagnosis, healthy community controls and 
OLD.  A change in expression was considered significant if the p-value <0.0002 after the application of 
the Bonferroni correction.  
A. CD126: TB (Dx), Healthy and OLD B.  CD120b: TB (Dx), Healthy and OLD 
C.   CD8: TB (Dx), Healthy and OLD D.   CD11a: TB (Dx), Healthy and OLD 
Figure 3.9: Kernel density graphs comparing the distribution of expression of markers between 
TB diagnosis, healthy controls and other lung disease controls (OLD).  
 


















Distribution of expression of CD48 (a), CD50 (b), HLA-DR (c) and CD29 (d).  PBMCs were isolated, 
stained and acquired on a flow cytometer to evaluate the expression of markers on the cells surface.  
The expression is denoted as a percentage of the total cells expressing the marker.  The comparison 
was made between the expression levels of TB patients at diagnosis, healthy community controls and 
OLD.  A change in expression was considered significant if the p-value <0.0002 after the application of 
the Bonferroni correction.  
 
A. CD48: TB (Dx), Healthy and OLD 
B.   CD50: TB (Dx), Healthy and OLD 
C.   HLA-DR: TB (Dx), Healthy and OLD D.   CD29: TB (Dx), Healthy and OLD 
Figure 3.10: Kernel density graphs comparing the distribution of expression of markers between 
TB diagnosis, healthy controls and other lung disease controls (OLD).  
 




3.2.3.1. IPA pathways associated with markers exhibiting a significant change 
in expression between two patient groups. 
 
 
3.2.3.1.1. Comparison of marker expression between TB patients at diagnosis and 
healthy community controls 
 
Fourteen markers resulted in 26 pathways with an association of two or more 
markers under investigation.  The first ten pathways, associated with one or more 
surface markers, are listed in table 3.7. 
 
3.2.3.1.2. Comparison of marker expression between TB patients at diagnosis and 
OLD controls 
 
Twelve markers resulted in 15 pathways with an association of two or more markers 
under investigation.  The first ten pathways, associated with one or more surface 

















3.2.3.2. Heat map illustrating the change in expression between TB diagnosis, 
week 24 and healthy community controls. 
 
A comparison between TB patients at diagnosis, EOT and healthy community 
controls showed a difference in expression levels for most markers.  Week 24 and 
healthy community controls clustered together, sharing similar expression profiles 


















Heat map generated to compare the expression levels of markers between TB diagnosis, week 24 



















Figure 3.11: Heat map comparing expression of TB diagnosis, week 24 and healthy community  
controls. 




3.2.3.3. Heat map illustrating the change in expression between TB diagnosis, 
OLD and healthy controls. 
 
The comparison of the expression of markers between diagnosis and other lung 
disease showed a mixed profile where some markers showed an up-regulation in 
OLD compared with diagnosis and other markers showed a down-regulation while 
other markers remained unchanged or had little change.  This also proved true when 
comparing OLD with healthy controls indicating a very different response to other 
















Heat map generated to compare the expression levels of markers between TB diagnosis, OLD 
controls and healthy community controls. An up-regulation is indicated by red and a down-regulation is 



























Figure 3.12: Heat map comparing expression of TB diagnosis, OLD and healthy community 
controls. 




Table 3.13:. List of markers and their accession numbers used for IPA analysis 
 
 
ANOVA Paired t-test: Paired t-test: Paired t-test: Independent t-test: Independent t-test: 
TB Dx vs week 24 TB Dx vs week 24 TB Dx vs week 4 Week 4 vs week 24 TB Dx vs healthy TB Dx vs OLD 
Marker:  Accession #: Marker:  Accession #: Marker:  Accession #: Marker:  Accession #: Marker:  Accession #: Marker:  Accession #: 
CD50 P32942 CD50 P32942 CD120b P20333 CD146 P43121 CD50 P32942 CD50 P32942 
CD48 P09326 CD48 P09326 F11 R Q9Y624 CD126 P08887 CD48 P09326 CD64 P12314 
CD58 P19256 CD58 P19256 CD11a P20701 CCR6 P51684 CD147 P35613 CLA Q8WTV0 
CD91 Q07954 CD91 Q07954 CCR4 Q9ULM6 CD29 P05556 CD45 P08575 CD120b P20333 
CD4 v4 Q8IUX4 CD4 v4 Q8IUX4 CD62L P14151 CD62P P16109 CD66b P31997 CD107a P11279 
CD146 P43121 CD18 P05107     CD81 P60033 CD18 P05107 Ly b R P36941 
CD120b P20333 CD120b P20333         CD146 P43121 CD141 P07204 
CD53 P19397 CD107a P11279         TGFBR2 P37173 CD220 P06213 
CD126 P08887 CD53 P19397         CD140a P16234 CD87 Q03405 
F11 R Q9Y624 CD126 P08887         CD126 P08887 CD29 P05556 
CD44 P16070 F11 R Q9Y624         Le B4 R Q15722 CD33 P20138 
CD11a P20701 CD29 P05556         CD29 P05556 CD81 P60033 
CD4 P01730 CD11a P20701         CD11a P20701     
CD81 P60033 CD81 P60033         CD20 P11836     
CD62L P14151 CD4 P01730                 
CCR7 P32248 CD28 P10747                 
CD29 P05556 CD62L P14151                 
    CCR7 P32248                 
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Due to the small sample size of this project, it was not possible to perform logistic 
regression and general discriminate analysis. Both parametric and non-parametric 
methods were used to verify the results. 
 
3.2.4.1. Association between the expression of markers at diagnosis and the 
treatment outcome 
 
Comparisons between definite cure and not cured were made and markers that were 
significant using ANOVA to compare the three treatment outcomes (definite cure, 
probably cure, not cured) were tested with the independent t-test. Due to the number 
of markers identified (six) by ANOVA and the application of the Bonferroni correction, 
a p-value < 0.008 was considered statistically significant. Five markers were 
significant when comparing the means between groups of patients classified as 
cured or not cured at the end of treatment (table 3.14).  
 







CD18 98.78462 66.21667 0.000888 
CD11a 97.43077 63.45700 0.001188 
CD50 97.63846 64.09667 0.001022 
CD48 97.04231 67.30000 0.001115 
CD53 97.94615 70.23333 0.001715 
 
3.2.4.2. Association between the expression of markers at diagnosis and time 
to positivity (TTP) 
 
No markers were correlated with the TTP when using a simple correlation.  Scatter 
plots were used to identify markers showing a convincing linear relationship and 
were investigated for correlation with multiple linear regression models. The markers 
that were used in the multiple linear regression model were CD146, CD62P, CD4, 




CD126, CD4v4, CD28 and CCR7 and none of these showed a significant linear 
relationship. 
 
3.2.4.3. Association between expression of markers at diagnosis and week 8 
culture results 
 
Independent t-tests were used to compare marker expression with either a positive 
or negative week 8 culture results; however, none of the markers were significant. 
 
 
3.2.4.4. Association between expression of markers at diagnosis and 
qualitative scan outcome 
 
When comparing the expression of markers at diagnosis with the PET/CT outcome 
groups (resolved, mixed or improved), only two markers were significantly different.  
Further t-tests identified these markers as being significantly different between the 
mixed and improved groups with a p-value of 0.015 and 0.014 for CD45RO and 
CD4v4 respectively.  
 
3.2.4.5. Association between markers and new clinical groups by combining 
qualitative and quantitative scan outcomes 
 
New scan outcome groups were defined by combining the original qualitative and 
quantitative groups to stratify patients into clinical severity groups (table 2.7).  There 
was no significant association found between the new scan outcome groups and the 
marker expression using ANOVA; however, non-parametric testing revealed CD18, 
CD11a, CD62P and CD81 had p-values <0.05 when comparing the good and poor 
outcome groups. 
 




Chapter 4:   Discussion 
 
Sputum smear microscopy and sputum culture are the only validated methods for 
monitoring treatment response in TB.  Both methods have limitations such as a lack 
of sensitivity in smear microscopy or long turnaround time for culture results.  This 
has resulted in a necessity for new treatment response markers.  
Little is known about which PBMC surface markers change during the course of anti-
TB therapy.  Previous studies have identified a number of markers that, when used 
in combination, could provide potential serological biomarkers for outcome prediction 
in TB patients (57).  Djoba et al. demonstrated that serological markers such as 
CRP, sICAM-1, granzyme B, sLAG-3 and suPAR could potentially contribute to 
forming a predictive model to be used as biomarkers for treatment response (58).   
Studies involving the detection of cytokine and chemokine concentrations in plasma 
from patients with pulmonary TB, pleural TB, other pleural diseases and healthy 
community controls revealed markers such as CXCL10/IP-10 and CCL3/MIP-1α 
were significantly increased in pleural TB patients compared with other pleural 
diseases making them potential plasma biomarkers for pleural TB disease (59). 
This project investigated 252 markers simultaneously in PBMCs from actively 
infected TB patients at three time points in relation to treatment, healthy community 
controls and other lung disease controls. Five markers changed significantly from 
baseline to the end of treatment (EOT) in TB cases and four markers differentiated 
between TB diagnosis and healthy community controls. None of the markers showed 
a significant difference from TB baseline to week 4 on treatment or between active 
TB and other lung diseases; however, before the Bonferroni was applied each of 
these groups had five and 13 markers respectively that had a p-value <0.01 and 
could therefore still have a biological significance. 
Comparison between TB diagnosis and week 4 did not yield any early treatment 
response markers (W4) that were significant after the Bonferroni correction; 
however, five markers (CD120b, CD126, CD62L, CD48 and CD29) were significantly 
different at EOT making them potential late treatment response markers.   Although 
CD48 and CD29 expression at baseline and EOT were significantly different, these 




changes were very small and almost all the cells had a high positive expression and 
the biological and clinical relevance of these markers was therefore judged to be 
questionable. The four markers that differentiated between TB patients and healthy 
community controls were CD48, CD18, CD126 and fMLPr.  As above, CD48 and 
CD18 both had high positive expression and very small differences deeming their 
significance as questionable.  Statistically one in 20 markers are expected to show a 
significant difference by chance (P-value <0.05).  Therefore, using the Bonferroni 
correction, and using an        only markers with p-value  
    
   
         should 
be considered to limit false positive discovery.  It is acknowledged that the Bonferroni 
correction is a highly stringent and conservative approach for adjustment for multiple 
tests and some researchers regard it as unhelpful (56). To prevent false negative 
discovery we therefore decided to include markers that did not withstand the 
Bonferroni correction but had a p value of <0.01.  The markers listed in table 3.7 and 
table 3.8 for IPA and Qlucore respectively therefore includes all markers for which 
expression differences reached this p-value. 
 
4.1. Objective 1 -  Optimisation of FACSTM CAP procedures. 
 
4.1.1. Objective 1.1 - Comparison of surface marker expression between 
fresh and cryopreserved PBMCs. 
 
Studies may require retrospective phenotypic and functional analysis of PBMCs from 
samples collected throughout the duration of a project.  This makes cryopreservation 
a useful tool for storing live cells for prolonged periods of time.  It has been shown 
that cell viability and the ability to proliferate and produce cytokines upon stimulation 
can be preserved when cryopreserving PBMCs (60).   
One aspect of this project was to determine the effect of cryopreservation on surface 
marker expression of PBMC’s for FACSTM CAP on cryopreserved samples for future 
studies.  PBMCs, from five healthy volunteers, were used to compare the expression 
of surface markers between freshly isolated PBMCs and cryopreserved PBMCs.  Of 
the 252 markers that were included in this study, only five showed a notable 
difference between fresh and cryopreserved cells.  Markers that showed an 




expression in only one or two samples were not considered as were markers that 
showed an increase in some patients but a decrease in others.   Of the markers that 
were significantly different between fresh and cryopreserved cells, four (CD41a, 
CCR6, CD9, CD62L) showed a down-regulation in their expression while only one 
marker (CD7) showed an up-regulation.  Due to the small sample set for this aspect 
of the project, it was difficult to perform a strong statistical analysis to determine if the 
change in expression between fresh and cryopreserved cells was significant.  
Cryopreservation time for these samples ranged from four to eight weeks, a 
relatively short time when compared with long-term storage of PBMCs. Prolonged 
storage of PBMC’s in liquid nitrogen may result in cells being more fragile and 
showing different expression levels of surface markers.  The control samples were 
obtained from healthy volunteers therefore it is possible that a repeat of this 
experiment using TB patients could result in significantly different results due to the 
fragility of cells from TB patients.  Costantini et al. demonstrated, in their comparison 
of fresh vs cryopreserved PBMCs, a marked decrease in the expression of CD62L in 
cryopreserved cells, which is in keeping with the results that we obtained (61).    
When performing analysis on the flow cytometry data, it was noted that in four of the 
five samples the granulocyte population was diminished in the frozen samples 
confirming the poor recovery of these cells after freezing whereas the fifth had no 
granulocyte population.  
The process of cryopreservation may lead to a loss of up to 50% of PBMCs and 
each plate required approximately 1 x 107 cells (total of 2 x 107 cells). It was soon 
evident that the concentration of PBMCs required to prepare duplicate plates would 
not be attainable in all the samples.  It was decided to continue the project using only 
freshly isolated PBMCs to minimise the exclusion of samples due to insufficient cell 
concentrations. 
 
4.1.2. Objective 1.2 - Comparison of surface marker expression between PPD 
stimulated and unstimulated PBMCs. 
 
Purified protein derivative (PPD) is an extract of Mtb and is the antigen used in the 
Tuberculin skin test, a diagnostic test for detecting active or latent infection with Mtb 




(62).  Individuals who have had a previous encounter with Mtb or have a currently 
active infection will respond with a positive response noted by an induration of 10mm 
or more.  In vitro stimulation of PBMCs with PPD results in the activation of T cells 
and the initiation of the Th1 cytokine response (63), mimicking the response of T cells 
to live Mtb . 
Of the 252 surface markers, only six markers (CD41a, CD45RA, CD61, CD4 v4, 
Cd49a and CD62L) had an expression level that was consistently up-regulated or 
down-regulated after stimulation of PBMC’s with PPD.   
CD41a is a platelet glycoprotein receptor, which forms a part of the GPIIb/IIIa 
complex and is associated with normal platelet adhesion and aggregation.  During 
the inflammatory response, platelets undergo a conformational change and function 
by forming clots during vascular injury (64).  CD45RA is defined as a marker of naïve 
T cells and during stimulation of T cells, human CD45RA+ cells respond with a high 
frequency in primed individuals (65).  The down-regulation of expression of CD45RA 
in PPD stimulated cells could be explained by this responsiveness to stimulation, 
which results after activation of T cells and an increased differentiation of naïve T 
cells. 
The small number of significantly different markers might be explained by the fact 
that analysis was performed by gating on the total PBMC population in which TB 
specific T cells that respond to PPD stimulation represent a small percentage. It may 
also be due to the fact that these patients had an active TB infection, which could 
have resulted in the PBMC’s already being maximally stimulated by the infection and 
thus not producing a further significant increase. 
When evaluating the expression levels of activation markers, it was noted that the 
change in expression was not significantly different.  Antas et al. observed an 
increase in expression of CD69 and CD25, both activation markers, when stimulated 
with PPD (66). However, the stimulation was performed over a longer period of time 
with the expression of CD69 and CD25 showing an up-regulation after 24 and 96 
hours respectively (66).  The lack of significant change in our samples may be 
attributed to the short incubation period or alternatively to the fact that our samples 
were from actively infected TB patients who may already have a maximally 
stimulated response prior to further PPD stimulation. 





It was decided early in the project to continue the preparation of PBMCs without 
stimulation with PPD.  This decision was made on the basis of cost and availability of 
PPD at the time that the project was being performed.  The volume of PPD needed 
to stimulate 2 x 107 cells at a concentration of 10µg/mL for each sample at each time 
point meant that the cost of the PPD would be in excess of the provided budget.  At 
the time that this decision was made, there was worldwide shortage of PPD, which 
resulted in a long delay in delivery which made it impractical to use in a time-
sensitive study. 
 
4.2. Objective 2: To assess the differential PBMC surface marker expression 
by FACSTM CAP in TB patients during treatment. 
 
4.2.1. Markers with a significant change in expression after the Bonferroni 
correction. 
 
4.2.1.1. CD126 (IL-6R) 
  
IL-6 is a pleiotropic, pro-inflammatory cytokine, released by phagocytes, endothelial 
cells, fibroblasts, B cells and T cells, which has an increased presence in various 
diseases such as auto-immune and inflammatory conditions (67).  The biological 
activities associated with IL-6 can be grouped as follows: 
 
 
 IL-6 belongs to the pro-inflammatory cytokine group, along with TNF 
 and IL-1, responsible for initiating the early inflammatory response (68). 
 IL-6 is involved in T and B cell promotion (67). 
 IL-6 participates in haematopoiesis (69).  
 It is the cytokine that induces the acute phase response (70). 
 
The function of the acute-phase response is to neutralise invading pathogens and to 
assist in recovery after an injury to minimise tissue damage.  The acute-phase 
response increases body temperature (fever), increases vascular permeability for 




extravasation of leukocytes and induces production of acute-phase proteins (APP) 
by the liver (71).  Some of the positive acute phase proteins include C-reactive 
protein, serum amyloid P (SAP), serum amyloid A (SAA), fibrinogen, alpha 1 
antitrypsin, alpha 2 macroglobulin, ferritin, ceruloplasmin and haptoglobin (72).  It has 
been shown that IL-6 is an important player in protection against Mtb and the 
presence of IL-6 is essential in the stimulation of a Th1 response after vaccination 
against Mtb (73).  Singh et al. suggested that IL-6 could be used as a stand-alone 
diagnostic biomarker for TB or as part of a biomarker signature as they found 
significantly increased levels of IL-6 in mice when peritoneal macrophages were 
infected with Mtb (74). However, this approach could be problematic as IL-6 
production would also occur in other infections, thereby decreasing specificity for TB. 
The stimulation of IL-6 occurs through the interaction with two cell surface 
molecules: IL-6R (CD126) and gp130. IL-6 binds to membrane bound IL-6R and 
together the IL6/IL6R complex associates with gp130, a 130kDa polypeptide chain 
present on the surface of cells.  IL-6R is membrane bound and is expressed 
predominantly by T cells, monocytes, activated B cells and neutrophils  (75).    gp130 
is not specific to the IL-6R pathway and is found on all cells making it a common 
signal transducer which can associate with many specific receptors.  This 
association of a specific receptor and a common signal transducer provides an 
explanation for the pleiotropy which is found amongst a number of different cytokine 
families (76).  Soluble IL-6R (sIL-6R) is formed during one of two processes namely 
proteolysis (shedding) and translation from an alternatively spliced mRNA (77). The 
binding of IL-6/sIL-6R complex to bind gp130 is an example of trans-signalling and 
potentially allows the IL-6/sIL-6R complex to stimulate most cells in the body.  
Soluble gp130 (sgp130), present in higher concentrations in the blood than 
membrane gp130 (mgp130),  acts as a natural inhibitor of IL-6 signalling by binding 
to the IL-6/sIL6R complex and preventing the complex from binding to membrane 
bound gp130 (mgp130) (78).    
Although CD126 expression was higher in TB patients at diagnosis than week 4 and 
EOT, the difference was only statistically significant between diagnosis and EOT, 
suggesting limited utility as early treatment response biomarker, at least in univariate 
analysis.  The increased expression level in TB patients is in keeping with the 




increased inflammatory response during active disease with a subsequent decrease 
due to treatment. When comparing expression of CD126 of TB patients at diagnosis 
with healthy community controls and other lung disease controls, TB patients had 
higher levels than the other groups but only differences between TB cases and 
healthy community controls were statistically significant.  
 
4.2.1.2. CD62L (L-selectin) 
 
Once the human body encounters a pathogen lymphocytes must leave the 
peripheral circulation and be directed to secondary lymphoid organs where the 
antigens are presented (79).  CD62L, also known as L-selectin, is a cell adhesion 
molecule found on the surface of lymphocytes, neutrophils, monocytes, eosinophils 
and haematopoietic stem cells (80).  More specifically, L-selectin is involved in the 
differentiation of naïve T lymphocytes and their homing to the site of infection (81).  
The presence of L-selectin on the surface of naïve T cells allows the cells to exit the 
bloodstream, by attaching to activated endothelial cells, and entering the secondary 
lymph organs.  The cells are returned to the blood stream a few hours later to 
continue their circulation through the body. During antigenic challenge, T cells are 
activated and L-selectin is shed.   The shedding of L-selectin occurs when 
leukocytes slow their velocity and roll along the endothelium in preparation of 
migration to the site of infection.  The process of shedding serves to redirect 
leukocytes to the site of infection by preventing them from entering the secondary 
lymphoid tissue (82) (79).  
A triphasic expression pattern of L-Selectin is initiated upon activation of T cells. The 
presence of an antigen results in the loss of approximately 70-90% of L-selectin 
within the first four hours as shedding occurs and T cells are re-directed to the site of 
infection.  After 12 – 24 hours, T cells re-express L-Selectin three to four times 
greater than the starting expression and within five to seven days, the expression 
decreases again to either a very low or no expression of L-Selectin as cells 
differentiate into either central or effector memory T cells.   Sanchez-Garcia et al. 
showed that γδ T cells shed their L-Selectin upon activation of cells with Mtb but re-
expressed L-Selectin after the antigen was removed indicating that the expression is 
regulated by the presence or absence of antigen (83). If the antigenic stimulation 




persists, L-Selectin is expressed at low levels for an extended period of time (84).  L-
Selectin is a reliable surface marker for detecting memory cells and the presence or 
absence of the marker can differentiate the cells into either central memory cells 
(Tcm, CD62L+) or effector memory cells (Tem, CD62L-) (85).  
The results of this study show an expression level of CD62L to be higher than that of 
healthy individuals but similar to patients with other lung diseases. The fact that T 
cell activation is not specific to only Mtb explains the similarity in expression levels of 
both TB diagnosis and other lung disease patients.  The expression levels 
decreased at week 4 and continued to drop further at EOT to an expression level 
lower than healthy community controls. The low expression level at EOT could be 
attributed to the differentiation of T cells into a memory phenotype.  
 
4.2.1.3. CD120b (TNFR2) 
 
CD120b, also referred to as tumour necrosis factor receptor 2 (TNFR2), is a member 
of the tumour necrosis factor (TNF) superfamily.  TNF is one of the primary initiators 
of the innate immune response and plays a vital role in the inflammation associated 
with bacterial, viral and parasitic infections (86). TNF interacts with TNFR1 and 
TNFR2 to optimally function during antigenic challenge.  TNFR1 is expressed in low 
levels on most nucleated cells and contains a death domain through which the 
caspase pathway is activated, the NF-κβ pathway is promoted and apoptosis is 
initiated (87). TNFR1 is known to regulate TNF-induced inflammation and apoptosis 
(88).  TNFR2 is preferentially expressed on the surface of lymphocytes and lacks a 
death domain.  TNFR2 is typically activates the NF-κβ pathway with a subsequent 
activation of pro-survival target genes in the nucleus of cells thereby suppressing the 
immune system to auto-antigens and preventing immunopathology (89).  TNFR2 
serves as a co-stimulator during T cell activation by enhancing the response of 
lymphocytes to TCR-mediated signalling and promoting cell activation, proliferation 
and migration (90). Kim et al. showed that TNFR2 is vital in ensuring the survival of 
CD4+ and CD8+ T cells during the first few rounds of clonal expansion when 
responding to intracellular bacterial pathogens.    
  




In this project, the expression of CD120b decreased during treatment with a 
significant change in expression between TB diagnosis and EOT.  The change in 
expression at week 4 was significant before the Bonferroni correction but not after; 
however the small sample size and stringent correction for multiple comparisons 
should not preclude inclusion of this marker in future validation steps.  Strikingly, 
expression at baseline is similar to that seen in healthy community controls and 
week 4 and week 24 expression is lower than in healthy community controls. During 
active TB infection there is an up-regulation of inflammatory cytokines and 
chemokines some of which initiate apoptosis and subsequent cell death.  TNFR2, 
which is thought to have a pro-survival effect, could be up-regulated as a 
compensatory mechanism to moderate the effects of inflammation.  It may be that 
the normal expression level of CD120b at baseline is inappropriately high for an 
infection that requires a strong pro-inflammatory response.  Reduction after the 
onset of antibiotic treatment may be in keeping with the establishment of a more 
appropriate response. We do not know at which stage after completion of treatment, 
if ever, CD120b expression returns to normal levels.   
 
4.2.2. IPA pathways and heat map data associated with the significant 
markers in overall treatment response (between diagnosis and week 
24). 
 
IPA is a web-based software platform that enables biological contextualization of 
research data by placing differentially expressed markers into the context of known 
biological pathways and disease associations. IPA was performed using the markers 
for which differences between groups or time points had a p-value <0.01 before 
Bonferroni correction, as only three markers remained significantly different after this 
correction for multiple comparisons. The canonical pathway generated by IPA 
showed 23 different pathways associated with two or more of the markers of interest 
of which the top nine pathways according to p-values and number of markers 
included into each pathway will be discussed briefly.   
 




4.2.2.1. The pathway associated with Leukocyte extravasation signalling  
 
The markers associated with the leukocyte extravasation signalling pathway include 
CD44, intercellular adhesion molecule 3 (ICAM3, CD50), integrin β1 (ITGβ1, CD29), 
ITGAL (Lymphocyte function-associated antigen 1, LFA-1, CD11a) and F11-R 
(Junctional adhesion molecule 1, JAM1).  
Extravasation is an important contributor to the inflammatory process and 
haemostasis, which is largely mediated by adherence factors.  Extravasation occurs 
when leukocytes migrate from the blood circulation through the endothelium and 
basement membrane towards the site of infection. This process is initiated by 
chemokines and other pro-inflammatory markers and begins when the leukocytes 
adhere to endothelial cells (91).  The leukocytes adhere and tether to the 
endothelium by recognising selectins on the surface of the endothelial cells, begin 
rolling along the vessel wall and slow down until they arrest and trans-endothelial 
migration occurs. This process is largely controlled by integrins and their ligands 
such as ITGβ1 (CD29), which serves as a membrane receptor involved in adherence 
and recognition during tissue repair and haemostasis (92). 
Selectins (P, E and L) all form important roles in the adherence and capturing of 
leukocytes where P-selectin glycoprotein ligand-1 (PSGL1), a ligand for all three 
selectins, binds to the selectins inferring their function of adherence either to the 
endothelium (P and E-selectins) or for leukocyte – leukocyte binding during 
secondary capture (L-selectin).  Secondary capture, mediated by L-selectin, occurs 
when a rolling leukocyte interacts with a free-flowing leukocyte, attaches to the 
endothelium and initiates rolling and adherence for accumulation migration to the site 
of infection (93).  CD44 is responsible for slowing the flow rate of the leukocytes 
thereby facilitating the attachment and migration of T cells.  It has been suggested 
that elevated levels of CD44, in co-operation with shedding of L-selectin, inhibits the 
clearance of activated cells from the peripheral blood by secondary lymphoid tissue 
thereby also enhancing the migration of cells to the active site of inflammation (84).  
LFA-1, a member of the β2 integrin family, is necessary to enhance firm adhesion of 
cells to activated endothelial cells (94). Ligands such as JAM1 (F11R) can bind to 
ICAM3, a ligand found on the surface of leukocytes, and contribute to the adherence 
of leukocytes to the endothelium.  




Our results indicate that these markers were significantly different when comparing 
TB diagnosis and EOT.  Additionally the difference in expression between TB 
diagnosis and week 4 was significant before the Bonferroni correction for F11R and 
CD11a indicating a potential role as a constituent of an early treatment response 
biomarker signature. However, as these markers are involved in general 
inflammation and are not specific for Mtb, it is unlikely that these markers would take 
on a role as a key biomarker. The high expressions of the markers associated with 
this pathway bring their biological significance into question.   
 
4.2.2.2. The pathway associated with crosstalk between dendritic cells and natural 
killer cells 
 
The markers of interest associated with the crosstalk between dendritic cells and 
natural killer cells include TNFR2 (CD120b), CCR7, ITGAL (LFA-1, CD11a) and 
ICAM-3 (CD50).   
DC’s are antigen presenting cells that play an important role in the initiation of the 
immune response by inducing and stimulating CD4 and CD8 T cells necessary for 
the adaptive immune response. They reside in peripheral tissue and release 
cytokines and chemokines when a pathogen is detected (95).   Natural killer cells are 
involved in the innate immune response although they may share similar functions to 
cytotoxic T cells.   Their role in the initiation of the immune response involves the 
production of cytokines, primarily IFN-γ, which is one of the most important cytokines 
involved in the immune response.  More recently it has become apparent that there 
is a crosstalk between DC’s and NK’s (96). The mechanism of crosstalk occurs when 
DC’s activate and stimulate NK’s, which results in the subsequent production of   
IFN-γ, inducing the strong Th1 polarisation seen in Mtb infections (97).  
In this pathway, TNFR2 and CCR7 are designated as having a role in the maturation 
and migration of DCs and the initiation of the adaptive immune response. In our 
analysis it was seen that CCR7 was down-regulated at EOT when compared with TB 
diagnosis and similar to healthy community controls at EOT, which is in keeping with 
a down-regulation of the immune response and it’s components as the disease is 
resolved.  




4.2.2.3. The pathway associated with granulocyte adhesion and diapedesis  
 
The markers of interest associated with this pathway included L-selectin (CD62L), 
ITGAL (CD11a), ITGβ1 (CD29), TNFR2 (CD120b).   
Granulocyte adhesion and diapedesis closely follows the leukocyte extravasation 
pathway described above where leukocytes are tethered, roll on and adhere to the 
endothelium in order to move between the endothelial cells and migrate to the site of 
infection. 
L-selectin (CD62L) was down-regulated after treatment, which correlates with the 
resolution of disease as there would no longer be a need for the infiltration of 
leukocytes once an infection has been cleared.  The changes in CD120b were 
discussed above. 
ITGAL (CD11a) and ITGβ1 (CD29) were both significantly up-regulated after 
treatment but the very high expression levels at all three time points and in all groups 
(between 97.5 and 99.55% for CD11a and 91.85 and 95.04 for CD29) puts the 
clinical utility and biological significance in doubt. 
 
4.2.2.4. The pathway associated with caveolar mediated endocytosis signalling 
 
The markers associated with the caveolar mediated endocytosis signalling pathway 
are CD48, ITGAL (CD11a) and ITGβ1 (CD29).  The ITGAL and ITGB1 were 
annotated as α-integrin and β-integrin respectively.   
Endocytosis mediated by caveolae rafts is classified as clathrin-independent 
endocytosis. Caveolae appear as 50-80 µm invaginations in the plasma membrane 
of many cell types and their appearance and function are dependent on the cell type 
(98). Cell membranes are composed of phospholipids, cholesterols and 
sphingolipids.  Rigid areas of membrane can form and move amongst the 
phospholipid bilayer regulating a variety of cellular functions and biological 
processes (99).  Lipid rafts can associate with caveolin-1 to form caveolae which are 
capable of internalising potential pathogenic bacteria such as Mtb.  Lipid rafts 
accumulate the signalling molecules necessary for the activation of lymphocytes as 




well as playing an important role in the innate immune response.  The role of lipid 
rafts in the immune response against Mtb is still largely unknown but it is thought that 
the mycobacterial 19 kDa lipo-protein mediated reactive oxygen species (ROS) 
formation allows toll-like receptor 2 translocation into the lipid rafts thereby promoting 
inflammation (100).  It has also been shown that lipid rafts play a role in the induction 
of TNF- α and therefore contribute to the initiation of the innate immune response 
(101).   
Upla et al. showed that α2β1 integrin is present in the raft-like membrane domains 
and the cluster formation of α2β1 integrin initiates the activation of endocytosis of 
caveolae therefore suggesting a novel mechanism of caveolae-mediated 
endocytosis (102). The up-regulation of α-integrin and β-integrin would therefore 
make sense as a compensatory mechanism in order to clear the Mtb infection via 
endocytosis.  As CD48 can be found in the same fraction as caveolin, it is suggested 
that the up-regulation is due to its role in the bacterial receptor of caveolae in mast 
cells (103). The expression of CD48, and as discussed above ITGAL and ITGβ1, 
were all highly positive at all three time points and in all groups, once again bringing 
the biological relevance into question. 
 
4.2.2.5. The pathway associated with NF-κβ activation by viruses 
 
The markers associated with the NF-κβ activation by viruses pathway are CD4, 
ITGAL (CD11a) and ITGβ1 (CD29).  In this pathway, ITGAL (CD11a) and ITGβ1 
(CD29) are annotated as integrin α2β1. 
Nuclear factor-κβ (NF- κβ) refers to a class of transcription factors that belong to the 
Rel family and play an important role in the initiation and promotion of inflammation 
as well as regulating the proliferation and survival of cells (104).  Inflammation is 
characterised by the activation of both pro- and anti-inflammatory mediators present 
in tissue and blood cells.  Cytokines, such as IL-1 and TNF-α, are released rapidly at 
the first sign of infection or tissue damage.  The NF- κβ complex is initially inactive 
but may be activated in response to invading bacteria and viruses, other pro-
inflammatory cytokines or stress-inducing agents (105). Two pathways exist for the 
activation of the NF-κβ pathway; namely, the canonical pathway and the alternative 




pathway.  The canonical pathway is activated by invading pathogens or the release 
of pro-inflammatory cytokines such as IL-1 and TNF-α while the alternative pathway 
is activated by cytokines from the TNF-family such as lymphotoxin β (106), CD40L, B 
cell activating factor and receptor activator of NF-κβ  ligand (RANKL) (107).  Certain 
viruses have the ability to activate NF- κβ to promote viral replication, prevent 
apoptosis and control the immune response.  The activation of NF- κβ by viruses 
appears to occur via different mechanisms. In the case of HIV fusion of the viral and 
cell membrane activates NF- κβ with the assistance of CD4 (108) while other viruses 
such as cytomegalovirus (CMV) may function by α2β1 ligation (109).  Lawrence et al. 
hypothesised that during resolution of disease, the NF- κβ pathway may be activated 
to express anti-inflammatory genes and induce apoptosis thereby playing a role in 
regulation of the inflammatory response (110). 
 
The α2β1 integrin is known as the collagen-binding integrin which is expressed by 
Th17 cells. Although this study was not focussed on viruses and their activation of 
the NF- κβ pathway, there must be significant overlap with responses induced by 
Mtb and the change in α2β1 integrin expression could also be related to the Th17 
response. 
 
α2β1 integrin was in fact not up-regulated at week 24 but down-regulated at 
diagnosis of TB disease with expression of CD11a and CD29 returning to healthy 
community control level at week 24. This could be due to an increase in Th1 and Th2 
cells, which would lead to a proportional decrease in Th17 cells or could be due to 
compartmentalisation of responses (peripheral blood versus site of disease).  
 
4.2.2.6. The pathway associated with dendritic cell maturation 
 
The markers involved in the dendritic cell maturation pathway include CD58, CCR7 
and TNFR2 (CD120b). 
 
Dendritic cells are potent antigen presenting cells and have the ability to stimulate 
naïve  or memory T cells (95).  The maturation of DC’s forms a critical component in 
the initiation of the adaptive immune response and subsequent proliferation of 




lymphocytes (111). DC’s, in their immature form, reside in peripheral tissues and are 
capable of antigen capture. Upon stimulation, DC’s migrate and mature to take on a 
role of antigen presentation and increased co-stimulatory molecule expression (95).  
Henderson et al. demonstrated that Mtb is phagocytosed by DCs suggesting a role 
of DCs in the early response to Mtb.  They also showed that infection with Mtb 
resulted in an up-regulation of CD40, CD54, CD58, CD80 and MHC I and II 
molecules, indicative of maturation of DCs and antigen processing and presentation 
(112).   
As previously discussed TNFR2 and CCR7, present on the surface of T cells and 
DCs, are involved in the maturation and migration of DCs as well as the stimulation 
of the adaptive immune response, all involved in the resolution of disease. As week 
24 is post treatment and thus translates to cure, the need for an immune response is 
lessened resulting in the down-regulation of both markers (113). 
 
4.2.2.7. The pathway associated with hepatic fibrosis and hepatic stellate cell 
activation 
 
The markers associated with the Hepatic fibrosis/hepatic stellate cell activation 
pathway include IL-6R (CD126), CCR7 and TNFR2 (CD120b). 
 
The hepatic stellate cell is a mesenchymal cell present in the liver and essential to 
hepatocellular function and liver fibrosis and repair.  It has also been documented 
that the hepatic stellate cells are important in the development of the liver by playing 
a role in the formation of the intrahepatic bile ducts (114).  Stellate cells have an 
ability to induce the infiltration of leukocytes, produce chemokines and express toll-
like receptors (115), all necessary for inflammation. Additionally hepatic stellate cells 
are capable of producing chemo-attractants to attract neutrophils which contribute to 
the liver inflammation (116).  Stellate cells are able to produce IL-6 when stimulated 
with TNF-α, IL-1β and lipopolysaccharide which in turn amplifies the acute phase 
response.  The acute phase response is activated rapidly after tissue injury or 
trauma, infection or immunological disorders which may create an imbalance in 
homeostasis (117).  The liver hepatocytes are responsible for the increased 
production of some blood proteins (acute phase proteins) such as C-reactive protein 




(CRP), serum amyloid A and haptoglobin (118). Bacterial infections, such as Mtb, 
initiate a strong acute phase response which could explain the up-regulation of our 
markers at diagnosis with a subsequent down-regulation after treatment, albeit on 
peripheral blood T cells in this case, rather than on hepatic cells. Presumably similar 
stimuli that would up-regulate these markers on hepatic cells would also be able to 
achieve the same marker expression on T cells. The markers in this pathway all 
correlate with the liver’s attempt to produce chemokines involved in the inflammatory 
process (119). 
 
4.2.2.8. The pathway associated with the role of osteoblasts, osteoclasts and 
chondrocytes in Rheumatoid Arthritis 
 
The markers associated with this pathway include TNFR2 (CD120b), LRP1 (CD91) 
and ITGβ1 (CD29). 
 
Rheumatoid arthritis is a degenerative bone disease which results in inflammation in 
the soft tissue surrounding the affected joints.  In healthy people, approximately 10% 
of bone mass is replaced each year and this is due to osteoclast and osteoblast 
activity.   Circulating blood monocytes have the ability to migrate to sites of injury or 
inflammation and differentiate into activated macrophages.  However, in the case of 
a bone injury or trauma, the monocyte and macrophage precursors can also 
differentiate into osteoclasts (120).  There are even reports of trans-differentiation 
from monocytes into a number of cell types, including endothelial, osteoblasts, 
chondrocytes and hepatocyte-like cells (121).   
 
As above, the markers measured in this study are all on T cells, but common effects 
of pro-inflammatory signals may be found on a range of cell types and in this case 
the changes seen in rheumatoid arthritis in response to inflammation may also be 









4.2.2.9. The pathway associated with T Helper cell differentiation 
 
The markers involved in T helper cell differentiation are TNFR2 (CD120b) and IL-6R 
(CD126). 
It is a well-known fact that an infection with Mtb induces a T helper 1 response of 
which IFN-γ plays an important and central role. T helper cell subsets are in a 
dynamic balance, which has led to the assumption that a decrease in Th1 
differentiation in Mtb is complemented by an increased Th2 differentiation (122). 
Naïve T cells have the potential to differentiate into at least four types of T helper 
cells namely Th1, Th2, Th17 and Tregs. T cell precursors originate in the bone 
marrow from hematopoietic stem cells and travel to the thymus where they undergo 
maturation.  Naïve T cells leave the thymus and enter the peripheral blood where 
they circulate until they encounter an antigen (123). Differentiation occurs when T cell 
precursors come into contact with antigen peptides complexed with MHC on the 
surface of antigen presenting cells (APCs).    Differentiation into lineage specific cells 
is dependent on the cytokine environment, types of APCs, the concentration of 
antigen as well as co-stimulatory molecules (124). 
The activation of naïve T helper precursor cells requires three sets of receptors 
namely the T cell receptor (TCR), co-stimulatory receptors (CD28) and cytokine 
receptors. During activation, the TCR and CD28 co-stimulatory receptor are re-
arranged into a complex between the antigen presenting cell and the T cell, known 
as the immunological synapse (IS).  
 
Th1 cell differentiation:  IL-12 and IFN-γ are two of the most important cytokines 
involved in Th1 cell differentiation.  APCs secrete IL-12 upon activation which 
induces the production of IFN-γ by natural killer cells. Interferon gamma receptor 
(IFNGR) is expressed by the T helper precursor cells (Thps) and the formation of the 
IFNGR and IFN-γ  complex initiates the Th1 differentiation providing a positive 
feedback loop (125).  IL-12R is not present on the surface of the cells however it 
plays a critical role in the continuation of the differentiation of the Th1 response. A 
number of transcription factors are involved in the differentiation of the Th1 cell 
subset such as T-box transcription factor (T-bet), Signal transducer and activator of 




transcription 1 (STAT1) and STAT4 as well as the inhibitory transcription factor 
GATA3 .  Although these transcription factors all have their own signalling pathway, 
they also work together for effective Th1 differentiation.   Animal studies have shown 
that a deficiency in IL-12, IL12R, signal transducer and activator of transcription 
protein (STAT) 4 and T-bet produce a defective Th1 response and increased 
susceptibility to Mtb (126).  Literature also shows that Mtb has the ability to inhibit the 
production of IL-12 thereby inhibiting the production of Th1 cells necessary to fight 
the infection.  Mtb infected cells have a tendency to increase the production of 
transforming growth factor β (TGF- β) which plays an instrumental role in the 
differentiation of Tregs which thus inhibit protective responses initiated by the host 
(127). Unfortunately the data on IL-12R (CD212) and IFN-γR (CD119) was not 
interpretable in this study due to difficulty in determining the appropriate cut-off for 
positivity on the FACS plots.  
TNFR2 showed a down-regulation in expression post-treatment, as discussed 
previously.  TNF is important for the recruitment of leukocytes and macrophages to 
the site of infection and for the maintenance of granulomas and therefore a decrease 
in this TNFR expression, that has anti-inflammatory effects, could indicate a resetting 
of the TNF-associated pro- and anti-inflammatory balance as the disease resolves. 
 
Th2 cell differentiation:  IL-4 and IL-2 are the most important cytokines and undergo 
stimulation in their production to initiate Th2 cell differentiation.  IL4R binds to its 
ligand which results in an activation of STAT6 which is the main transcription factor 
associated with differentiation and induces an up-regulation of GATA3.  GATA3 is 
considered to be the master regulator of Th2 differentiation and works in conjunction 
with STAT6 to regulate the Th2 genes.  It was shown that mice that are deficient in 
GATA3 have a tendency to produce a Th1 lineage of cells instead of Th2 (128).  IL-6 
is known to enhance the Th2 response by increasing the production of IL-4 by naïve 
T cells while simultaneously inhibiting the Th1 response by interfering with STAT1 
activation (129).  
 
Other T cell phenotypes: Th17, Treg and T follicular cell differentiation:  The major 
signalling cytokines involved in Th17 cell differentiation are IL-6, IL-21, IL-23 and 
TGF-β with retinoic acid receptor-related orphan receptor gamma-T (RORγt) being 




the master regulator. TGF-β plays a role in the development of regulatory T cells 
(Tregs).  If present in high concentrations and alone, it can skew the cell 
differentiation to a Treg lineage. However, at low concentrations and in the presence 
of IL-6, it will initiate Th17 differentiation while simultaneously increasing the 
production of IL-21 and IL23R, both of which are important in the subsequent phases 
of Th17 differentiation.  TGF-β in the presence of IL-6 leads to the activation of 
RORγt which induces the production of IL-17A and IL-17F (130).  We found a higher 
expression of CD126 (IL-6R) in TB patients at diagnosis than at EOT, healthy 
community controls or OLD controls, which is indicative of an increase in the 
production and differentiation of Th17 cells during active TB.  The cytokines 
produced by Th17 cells are pro-inflammatory and their importance in the control of 
TB has previously been demonstrated (37).  
Tfh cells are a subset of CD4 T cells that provides assistant in the formation of B 
cells. The primary cytokines involved in the induction of Tfh production are IL-6 and 
IL-21 although it still remains unclear of the exact role each of these cytokines play in 
Tfh development. Eto et al. showed that a deficiency in both IL-6 and IL-21 resulted 
in a decreased differentiation of Tfh cells however an absence of only one cytokine 
had no effect (131). B cells may have a regulatory role in the immune response to 
intracellular pathogens such as Mtb.  B cells may form aggregates in Mtb infected 
lung and regulate the formation of granulomas, cytokine production and the 
activation of T cells. Thus a down-regulation of IL-6R post-treatment may indicate a 
decrease in the Tfh cell differentiation due to the clearance of Mtb and therefore a 
diminished need for B cell production. 
 
4.2.3. IPA pathways and heat map data associated with significant markers 
when comparing surface marker expression between two timepoints  
(Dx - week 4, Dx - week 24 and week 4 - week 24). 
 
When performing IPA on markers with a p-value <0.01 before the Bonferroni 
correction for the paired t-test data, it was noted that there were a number of 
different pathways when comparing groups as outlined in section 3.2.2.1.  The 
pathways identified in the TB diagnosis versus week 24 analysis correlate closely 




with the pathways associated with the overall treatment response pathways in 
section 4.3.  The markers that changed significantly between diagnosis and week 4 
represent pathways associated with communication between innate and adaptive 
immune cells.  The granulocyte adhesion and diapedesis, leukocyte extravasation, 
crosstalk between DC and NK cells, TNFR2 signalling, T helper cell differentiation 
tight junction signalling pathways were all involved in early treatment changes when 
there is an influx of leukocytes and immune cells to the site of infection as well as 
communication and crosstalk of immune constituents of innate and adaptive immune 
response signalling.  Changes in these pathways, some increased and others 
decreased, point towards a reprogramming of the immune system as antibiotics 
decrease bacterial burden. The pathways associated with later treatment changes 
(between week 4 and EOT time points) overlapped strongly with early treatment 
changes although pathways associated with apoptosis and clearance of pathogens 
also became evident.  The granulocyte and agranulocyte adhesion and diapedesis, 
semaphorin signalling in neurons, regulation of cellular mechanics by Calpain 
protease, T helper cell differentiation and TREM1 signalling pathways all support the 
inflammatory response and migration of immune cells to the site of infection while 
the macropinocytosis signalling and role of JAK family kinases in IL-6 type cytokine 
signalling pathways play a role in antigen presentation and interactions of the 
humoral and cellular mediated adaptive immune response.   
 
Qlucore Omics Explorer heat maps provide an interactive visualisation of large 
multivariate data sets assisting in the identification of patterns.  In this project, the 
expression of surface markers was compared for three time points and participant 
groups and the changes were depicted as either red, to denote an up-regulation, or 
green, to denote a down-regulation, of expression.  The varying shades of either red 
or green indicate the degree of either the up- or down-regulation.  Black boxes 
indicate that there was no change relative to the mean expression of the entire data 
set.  Heat maps were generated using the surface markers that had a p-value <0.01 
before the Bonferroni correction. 
 




4.2.3.1. Comparison of marker expression between TB patients at diagnosis, week 
4 and week 24 
 
A heat map (Figure 3.8) showing the comparison between the time points of TB 
patients at diagnosis, week 4 and EOT revealed a trend for differences in expression 
of the markers, with both increased and decreased expression after initiation of 
treatment. When performing IPA on the clusters of up- and down-regulated markers, 
it was evident that the markers in each cluster are associated with pathways that are 
involved in the initiation of the immune response and migration cells to the site of 
infection. 
 
4.2.4. IPA pathways and heat map data associated with significant markers 
when comparing surface marker expression between two patient 
groups (TB diagnosis, healthy community controls and other lung 
disease controls). 
 
When comparing IPA results it was noted that the NF-κβ activation by viruses, 
caveolar mediated endocytosis signalling and PTEN signalling pathways were the 
common ones involved with the markers differentiating between TB, healthy 
community controls and other lung disease controls.  Pathways (leukocyte 
extravasation signalling, Paxilin signalling, granulocyte adhesion and diapedesis and 
integrin signalling) associated with the comparison between TB and healthy 
community controls involved those that are directly related to adhesion and migration 
of cells through the endothelium and thus affiliated with early inflammation and 
initiation of the innate immune response.  Pathways associated with the differences 
between TB patients and other lung disease controls include those that are involved 
in innate responses such as crosstalk between DC and NKs and DC maturation. The 
coagulation system and role of tissue factor in cancer pathways are both related to 
the release of tissue factor by monocytes in early inflammation in an attempt to 
prevent the spread of infection. This occurs in the early stages of inflammation, 
simultaneously with the production of pro-inflammatory cytokines and the recruitment 
of immune cells (132).  The PPAR signalling pathway and type II diabetes mellitus 
signalling pathways are related to general chronic inflammation and the 




differentiation and development of cells, neither of which are directly related to TB 
but rather a broad spectrum of chronic inflammatory diseases.   While there are a 
number of pathways highlighted as different between TB and healthy community 
controls and TB and OLD controls, most of the pathways are related to early 
inflammatory responses and the innate immune response.  There is a strong overlap 
between the pathways that differ between groups.  
 
4.2.4.1. Comparison of marker expression between TB patients at diagnosis, week 
24 and healthy community controls 
 
The heat map (Figure 3.11) shows that marker expression of week 24 and healthy 
community controls cluster together and are separate from the diagnosis time point, 
implying that patients have moved towards a healthy marker expression profile after 
treatment.  
 
4.2.4.2. Comparison of marker expression between TB patients at diagnosis, OLD 
controls and healthy community controls 
 
The heat map (Figure 3.12) generated showed that the two disease groups cluster 
together and are separate from the healthy community control group.   
 
4.2.5. Association between expression of markers at diagnosis and study 
outcomes 
 
Due to the small sample size of this project, it was not possible to perform logistic 
regression and general discriminate analyses. Parametric and non-parametric 
methods were performed to verify data and in most cases the results were the same.  
The standard deviations are large indicating that a more extensive validation study is 










Biomarkers, or biological markers, are defined as characteristics of normal biological 
function, pathological processes or pharmacological responses to therapeutic 
interventions which can be objectively, accurately and reproducibly measured (134).  
The WHO states that a biomarker may constitute any parameter that can be 
measured and reflects an interaction between a biological system and a potential 
chemical, physical or biological hazard (135).   
 
Limitations in diagnosis and monitoring treatment response have inspired research 
groups around the world to identify host biomarkers which are capable of early 
diagnosis of TB, providing correlates of risk of TB, providing correlates of protection 
against active TB disease and for determining the response of a patient to treatment 
(3).  An optimal biomarker for TB should be able to differentiate between latent or 
active infection, monitor treatment response and reliably predict a clinical outcome of 
actively infected patients (3).  Currently there is no single biomarker which is able to 
monitor treatment response to TB chemotherapy; however, a more feasible idea 
would be to create a biomarker panel or signature made up of a number of 
measurable characteristics that could specifically and sensitively monitor treatment 
response from as early as four weeks. 
 
This project looked at 252 cell surface markers in PBMCs of actively infected TB 
patients as well as healthy community controls and other lung disease controls.  
Using the very stringent Bonferroni correction, we identified five markers that 
changed significantly during the course of treatment in TB patients.  Changes of two 
markers were not deemed as biologically significant as the mean expression was 
predominantly positive through the course of treatment and it is unlikely that the very 
minor change in expression is biologically relevant or useful from a biomarker 
perspective.  Three markers, CD62L, CD120b and CD126 were significantly down-
regulated between diagnosis of TB and EOT.  All three markers play important roles 
in the inflammatory response to bacterial, viral or parasitic pathogens as well as the 
control of auto-immunity.  It is possible that some of the changes seen may be due to 




changes in cell populations in the circulation during the inflammatory response, 
changes in the surface protein regulation of a specific cell type or even as a result of 
changes in a specific marker expression in several cell types.  It is possible that 
some changes in surface marker expression may be missed or understated due to 
the up-regulation of a marker in one cell type but a down-regulation of the same 
marker in another cells type resulting in a net effect of no change.  This may due to 
the fact that multiple cell types may express the same marker and differentiation 
between these possibilities would be difficult. 
The analysis of 252 markers on the surface of peripheral blood mononuclear cells 
has been made possible using the FACSTM CAP technology designed by Becton 
Dickinson Biosciences. The present study is the first to evaluate the utility of this 
technology in a clinical study of this magnitude and a first evaluation in the 
heterogeneous sample type, PBMCs, right after isolation from whole blood. The work 
highlights some critical aspects of the FACSTM CAP technology: 
 
 Feasibility for biomarker discovery. 
 Technically relatively demanding due to the need for PBMC isolation. Future 
studies will evaluate simplified approaches like testing of whole blood. 
 The need for manual rather than automated analysis in a heterogeneous sample 
type like PBMCs due to difficulty in obtaining standard gating. This is a serious 
concern as this process is very labour intensive and requires relatively advanced 
training. 
 The need for validation experiments through selection of the most promising 
markers for properly powered studies to confirm candidate marker performance. 
 The need for further optimisation of cryopreserved PBMC samples, which was 
difficult to achieve due to the loss of cells in the cryopreservation process with 
resultant low cell concentrations. 
 The need for further optimisation of stimulation assays as PPD stimulation alone 
did not appear promising (only three markers showed up-regulation). Antigen 
concentrations need to be titrated and different antigens should be investigated. 
 The marker expression between TB at diagnosis and other lung diseases only 
showed a trend for differences after Bonferroni correction. However, the small 




number of participants (only 9 other lung diseases) may have precluded the 
discovery of truly differentially expressed markers. Furthermore, a lack of 
specificity may not be a major obstacle in the evaluation of TB treatment 
response, particularly in clinical trials of new drugs, as biomarkers always have to 
be interpreted in a proper clinical context and other diseases would have been 




The FACSTM CAP technology allowed the identification of three promising cell 
surface markers that require further validation as biomarker candidates for TB 
treatment response evaluation. This will be achieved through investigation of these 
and the most promising other markers that showed a trend for differences after 
Bonferroni correction in a candidate biomarker project of a new cohort of TB patients 
undergoing treatment.  
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